| Providence Health & Services Oregon | |
|
4823 Meadows Rd Lake Oswego OR 97035-2529 | |
| (503) 216-1580 | |
| Not Available |
| Full Name | Providence Health & Services Oregon |
|---|---|
| Speciality | General Practice |
| Location | 4823 Meadows Rd, Lake Oswego, Oregon |
| Authorized Official Name and Position | Donald Wayne Anderson (ASST SECRETARY FOR ENROLLMENT) |
| Authorized Official Contact | 4255255392 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Providence Health & Services Oregon Po Box 3158 Portland OR 97208-3158 Ph: () - | Providence Health & Services Oregon 4823 Meadows Rd Lake Oswego OR 97035-2529 Ph: (503) 216-1580 |
| NPI Number | 1023488343 |
|---|---|
| Provider Enumeration Date | 09/29/2015 |
| Last Update Date | 10/05/2021 |
| Medicare PECOS PAC ID | 0648183608 |
|---|---|
| Medicare Enrollment ID | O20031106000652 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023488343 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| 261Q00000X | Clinic/center | (* (Not Available)) | Secondary |
| Provider Name | Daniel M Rosenberg |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194750331 PECOS PAC ID: 5799698502 Enrollment ID: I20031107000522 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lydia A Villegas |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053344499 PECOS PAC ID: 7719891472 Enrollment ID: I20031117000641 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mindy S Loebner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841226438 PECOS PAC ID: 5597679191 Enrollment ID: I20031118000391 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert L Wells |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538192158 PECOS PAC ID: 9234043852 Enrollment ID: I20031118000491 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Deborah A Alexander |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255369559 PECOS PAC ID: 6901703362 Enrollment ID: I20031215000832 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anita Y Chan |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1912921156 PECOS PAC ID: 7012815541 Enrollment ID: I20031222000640 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven J Redmond |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1114968633 PECOS PAC ID: 1456259571 Enrollment ID: I20031229000423 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenny J Tsai |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1033124540 PECOS PAC ID: 9234038621 Enrollment ID: I20040105000732 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John S Domreis |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1629168646 PECOS PAC ID: 9133021868 Enrollment ID: I20040123000176 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael S Chen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023005410 PECOS PAC ID: 5799678520 Enrollment ID: I20040205000606 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Larlene M Dunsmuir |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205866969 PECOS PAC ID: 0840185575 Enrollment ID: I20040220000148 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly S Crihfield |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1649224882 PECOS PAC ID: 2668368283 Enrollment ID: I20040223000312 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tracy W Sax |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1487647624 PECOS PAC ID: 2567358088 Enrollment ID: I20040223000940 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William M Davies |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1154327625 PECOS PAC ID: 3577459353 Enrollment ID: I20040227000072 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brett R Baxter |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942246947 PECOS PAC ID: 6406744291 Enrollment ID: I20040304000771 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ronald L Spangler |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1437136025 PECOS PAC ID: 5193613362 Enrollment ID: I20040309000555 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rodney A Krehbiel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366435703 PECOS PAC ID: 9436048915 Enrollment ID: I20040312000599 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas L Kasten |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861467805 PECOS PAC ID: 7517857659 Enrollment ID: I20040319001165 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian J Kearns |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1013943661 PECOS PAC ID: 9830080407 Enrollment ID: I20040323000762 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven D Freer |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1568497279 PECOS PAC ID: 4486646585 Enrollment ID: I20040331000091 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sharon F Lissman |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1205871993 PECOS PAC ID: 4284626995 Enrollment ID: I20040401001205 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vinay Siddappa |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1174556799 PECOS PAC ID: 4688667934 Enrollment ID: I20040405000549 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Angela B Keating |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1376570036 PECOS PAC ID: 3870586977 Enrollment ID: I20040405001712 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard M Fisher |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1396770186 PECOS PAC ID: 3375536832 Enrollment ID: I20040408000485 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristine A Kruger |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457307977 PECOS PAC ID: 3577557792 Enrollment ID: I20040412000805 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark Huntington Whiteford |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1710970892 PECOS PAC ID: 4688669716 Enrollment ID: I20040419000372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick S Ohollaren |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1891782868 PECOS PAC ID: 6406842822 Enrollment ID: I20040421001763 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia P Bartley |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1467523951 PECOS PAC ID: 3476540337 Enrollment ID: I20040430000728 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Irene Winonah Hendrickson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134202310 PECOS PAC ID: 9931197720 Enrollment ID: I20040501000421 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shanta L Schriever |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427097765 PECOS PAC ID: 7618965476 Enrollment ID: I20040503000457 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sukhraj K Jhooty |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1417912189 PECOS PAC ID: 4880682319 Enrollment ID: I20040504000639 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sandra E Dancer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942241716 PECOS PAC ID: 7113916529 Enrollment ID: I20040511000431 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael John Lefor |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1003808452 PECOS PAC ID: 2062401193 Enrollment ID: I20040512000393 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica V Burness |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629034152 PECOS PAC ID: 6901896802 Enrollment ID: I20040513000744 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer R Hendrickson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1346345568 PECOS PAC ID: 4082605217 Enrollment ID: I20040518001181 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paul Kassar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1558397893 PECOS PAC ID: 4486635505 Enrollment ID: I20040525001673 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mhairi A Mcfarlane |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053464396 PECOS PAC ID: 0446231005 Enrollment ID: I20040528000386 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy E Schmitt |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942271986 PECOS PAC ID: 9133101512 Enrollment ID: I20040601001404 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard H Sohn |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1609818939 PECOS PAC ID: 0143202499 Enrollment ID: I20040602000390 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Duc Hoai Nguyen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275565814 PECOS PAC ID: 6406838556 Enrollment ID: I20040603000203 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Xiaoyan Huang |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1346232857 PECOS PAC ID: 3173505633 Enrollment ID: I20040607001142 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas Hyland Schaumberg |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1174516827 PECOS PAC ID: 4688572258 Enrollment ID: I20040608000107 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William Minor Lile Bowerfind |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1801898663 PECOS PAC ID: 4880677251 Enrollment ID: I20040608001139 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard B Bell |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1992704878 PECOS PAC ID: 8527041821 Enrollment ID: I20040609000100 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark A Thompson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598781684 PECOS PAC ID: 2062495294 Enrollment ID: I20040609001229 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Monique Gedenk |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740226745 PECOS PAC ID: 4385627538 Enrollment ID: I20040609001337 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly J Wehbe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477586097 PECOS PAC ID: 8628051778 Enrollment ID: I20040609001373 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Reetinder S Virk |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1689723231 PECOS PAC ID: 9739082967 Enrollment ID: I20040623000860 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristin K Loch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730197294 PECOS PAC ID: 1850377102 Enrollment ID: I20040628000111 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aly Rahimtoola |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1750373056 PECOS PAC ID: 8123005915 Enrollment ID: I20040630000352 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anne M Knudsen |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1821006958 PECOS PAC ID: 2264419639 Enrollment ID: I20040702000727 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ruth A Fischerwright |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851322366 PECOS PAC ID: 4284612185 Enrollment ID: I20040708000467 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephan W Coffman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1649235300 PECOS PAC ID: 3870571656 Enrollment ID: I20040708001178 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emery C Douville |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1306848098 PECOS PAC ID: 3375441876 Enrollment ID: I20040712000608 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Scott Marsal |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1063595254 PECOS PAC ID: 2668442963 Enrollment ID: I20040726001136 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua D Reagan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124093281 PECOS PAC ID: 6103896337 Enrollment ID: I20040727000620 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Darren R Jones |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1306844683 PECOS PAC ID: 5294705448 Enrollment ID: I20040727000758 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Adam Mizgajski |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1861428278 PECOS PAC ID: 9638141591 Enrollment ID: I20040811000111 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Felicia A Ferguson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1972511491 PECOS PAC ID: 1658343413 Enrollment ID: I20040811000899 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura H Davies |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1982670006 PECOS PAC ID: 9032181805 Enrollment ID: I20040811000957 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew J Gadbaw |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1558392969 PECOS PAC ID: 8224001599 Enrollment ID: I20040816000337 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michelle D Bonta |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1265468615 PECOS PAC ID: 6709851363 Enrollment ID: I20040827000927 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristina R Rashid |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1417980335 PECOS PAC ID: 5496722076 Enrollment ID: I20040914000039 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paul T Giger |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1154357366 PECOS PAC ID: 2567439664 Enrollment ID: I20040916000483 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Deborah R Wolfson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285666594 PECOS PAC ID: 9537137153 Enrollment ID: I20040922000132 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristen E Waits |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790838076 PECOS PAC ID: 5991773236 Enrollment ID: I20040923000670 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marion C Hull |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295775278 PECOS PAC ID: 8224007927 Enrollment ID: I20040929000750 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David B Wilkinson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1609841659 PECOS PAC ID: 5597734046 Enrollment ID: I20040930000803 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nori A Trevarthen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881641397 PECOS PAC ID: 4981663291 Enrollment ID: I20041004000391 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kirsten L Roberts |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003864596 PECOS PAC ID: 8224097571 Enrollment ID: I20041004000652 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sean P Tushla |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1376576983 PECOS PAC ID: 6608836333 Enrollment ID: I20041015000878 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick S Williams |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912014317 PECOS PAC ID: 7517927114 Enrollment ID: I20041019000363 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alfredo J Soto |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1841308632 PECOS PAC ID: 4688638422 Enrollment ID: I20041112000237 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Arthur Schroeder |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1578568499 PECOS PAC ID: 2163486739 Enrollment ID: I20041113000064 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maria C Leiva |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790766244 PECOS PAC ID: 4284690447 Enrollment ID: I20041208001201 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edmund C Beck |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508894718 PECOS PAC ID: 8527025691 Enrollment ID: I20041210000514 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marietta H Choe |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366472623 PECOS PAC ID: 3274590260 Enrollment ID: I20041210000690 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maria L Constante |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104856285 PECOS PAC ID: 6608833694 Enrollment ID: I20041210000718 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maryann Dunlap |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629002639 PECOS PAC ID: 4284691288 Enrollment ID: I20041210000771 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristin M Kocher |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629004155 PECOS PAC ID: 8123085164 Enrollment ID: I20041211000134 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbara A Lang |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1568491926 PECOS PAC ID: 1850358896 Enrollment ID: I20041211000138 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth R Oneill |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346278660 PECOS PAC ID: 5698732667 Enrollment ID: I20041213000137 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tamara J Rodgers |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1568493435 PECOS PAC ID: 6709843675 Enrollment ID: I20041213000215 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas M Schwartz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346265774 PECOS PAC ID: 7214994185 Enrollment ID: I20041213000249 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin R Sellars |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1396778916 PECOS PAC ID: 8921065897 Enrollment ID: I20041213000259 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia E Talbot |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700819125 PECOS PAC ID: 2567429442 Enrollment ID: I20041213000345 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charissa Rose |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1114952355 PECOS PAC ID: 3072570977 Enrollment ID: I20041213000460 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimya-anhcina Lan Nguyen |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1073596243 PECOS PAC ID: 0749265478 Enrollment ID: I20041215000633 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Claudine Y Moreno |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376571646 PECOS PAC ID: 9133186463 Enrollment ID: I20041217000443 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mario Seyer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942251293 PECOS PAC ID: 0749248623 Enrollment ID: I20041222000877 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Scott J Kemeny |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1639254659 PECOS PAC ID: 0547228447 Enrollment ID: I20041223000078 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin Michael Reavis |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1891749149 PECOS PAC ID: 2466410048 Enrollment ID: I20041229000459 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christina E Fyfe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912002775 PECOS PAC ID: 5395796205 Enrollment ID: I20050208001076 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carmen G Kendall |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780639575 PECOS PAC ID: 3577515261 Enrollment ID: I20050210000379 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mehdi Mike Mirtorabi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679509111 PECOS PAC ID: 7618929233 Enrollment ID: I20050211000356 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alison M Mitchell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003919887 PECOS PAC ID: 3577451350 Enrollment ID: I20050225000448 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura Donaghu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952331795 PECOS PAC ID: 7214981448 Enrollment ID: I20050309001072 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Scott A Garvey |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1093717795 PECOS PAC ID: 6507764081 Enrollment ID: I20050315000159 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brent L Hoffman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841239076 PECOS PAC ID: 7719932318 Enrollment ID: I20050316000865 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert J Litt |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1467444331 PECOS PAC ID: 1557317849 Enrollment ID: I20050330000285 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susan P Vawter |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1932169059 PECOS PAC ID: 8820045073 Enrollment ID: I20050331000465 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hans S Moller |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1831113133 PECOS PAC ID: 4486552387 Enrollment ID: I20050331000769 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brenda J Brischetto |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306891742 PECOS PAC ID: 4082652037 Enrollment ID: I20050420000476 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nancy L Ungoco |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780683318 PECOS PAC ID: 1759322928 Enrollment ID: I20050518000362 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah A Dervan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1457381329 PECOS PAC ID: 5597705764 Enrollment ID: I20050603000975 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kirk L Weller |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1235169566 PECOS PAC ID: 0547206823 Enrollment ID: I20050708000283 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark L Shatsky |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1932124369 PECOS PAC ID: 9537062161 Enrollment ID: I20050713000152 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bridget C Martin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518906759 PECOS PAC ID: 7719913599 Enrollment ID: I20050713000230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa S Turner |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1093731093 PECOS PAC ID: 6305872870 Enrollment ID: I20050715000414 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Blair D Halperin |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1447258710 PECOS PAC ID: 5991732786 Enrollment ID: I20050723000039 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel S Oseran |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1730187097 PECOS PAC ID: 8628005410 Enrollment ID: I20050723000042 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie R Zilverberg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366435372 PECOS PAC ID: 3375570922 Enrollment ID: I20050726000032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tanya L Page |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548276124 PECOS PAC ID: 9830127026 Enrollment ID: I20050729000042 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth A Picologlou |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1609936327 PECOS PAC ID: 7315975026 Enrollment ID: I20050802001294 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Fawn M Wolf |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689636557 PECOS PAC ID: 4486682028 Enrollment ID: I20050803000828 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael R Parsons |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1225029945 PECOS PAC ID: 2860421443 Enrollment ID: I20050804000830 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ruben O Halperin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457306763 PECOS PAC ID: 4789576083 Enrollment ID: I20050808001084 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brinton C Clark |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1831272012 PECOS PAC ID: 7810946738 Enrollment ID: I20050815000222 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel Elizabeth Sanborn |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1275548794 PECOS PAC ID: 7719917848 Enrollment ID: I20050817000950 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lesley Nicoloff Otto |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1699729608 PECOS PAC ID: 4587694583 Enrollment ID: I20050819000036 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen D Sethi |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1538108246 PECOS PAC ID: 7911939251 Enrollment ID: I20050907000785 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Colleen A Finnegan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104909936 PECOS PAC ID: 0840222014 Enrollment ID: I20050908000622 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa R Yanase |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1851384937 PECOS PAC ID: 1052343167 Enrollment ID: I20050908000997 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew Gerard Janssen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003891524 PECOS PAC ID: 9436194388 Enrollment ID: I20050909000560 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly A Shields |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104841543 PECOS PAC ID: 1951334952 Enrollment ID: I20050912000151 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jonathan Lindgren |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861615668 PECOS PAC ID: 6406880152 Enrollment ID: I20050921001091 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dale D Hirsch |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1114919610 PECOS PAC ID: 4981502556 Enrollment ID: I20051021000505 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gary Y Ott |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1891787180 PECOS PAC ID: 2961300504 Enrollment ID: I20051021000947 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Karen A Rydell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922090232 PECOS PAC ID: 9638195290 Enrollment ID: I20051021000948 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paul Daniel Hansen |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1104818632 PECOS PAC ID: 2668370230 Enrollment ID: I20051021000952 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brendan D Curti |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1861494650 PECOS PAC ID: 5597705251 Enrollment ID: I20051024001015 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Roxanne R Griswold |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205828936 PECOS PAC ID: 3476570888 Enrollment ID: I20051025000824 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy A Johnson |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1477582856 PECOS PAC ID: 1850331596 Enrollment ID: I20051027001058 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carolyn A Sites |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1790718310 PECOS PAC ID: 6103843297 Enrollment ID: I20051027001077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jill T Walworth |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1821017591 PECOS PAC ID: 8325065410 Enrollment ID: I20051027001127 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alan B Rankin |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1376576272 PECOS PAC ID: 5496772584 Enrollment ID: I20051027001140 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert G Fojtasek |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1306888649 PECOS PAC ID: 5395762496 Enrollment ID: I20051027001154 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian S Liebreich |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1669456232 PECOS PAC ID: 2668490897 Enrollment ID: I20051107000563 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kirsten E Crowley |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1396838280 PECOS PAC ID: 8527086644 Enrollment ID: I20051108000238 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy D Carolan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1295762946 PECOS PAC ID: 0749208668 Enrollment ID: I20051109000086 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael A Wilson |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1871539973 PECOS PAC ID: 8325948235 Enrollment ID: I20051116000893 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gillian C Rosicky |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295789428 PECOS PAC ID: 8628097821 Enrollment ID: I20051116001065 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sreedevi Pitta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780631655 PECOS PAC ID: 3678593431 Enrollment ID: I20051123000235 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony A Ferroggiaro |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1245254606 PECOS PAC ID: 4688602105 Enrollment ID: I20051205000039 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Craig R Walsh |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1922047935 PECOS PAC ID: 5193752061 Enrollment ID: I20051205000060 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Todd A Caulfield |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1710921085 PECOS PAC ID: 4284661158 Enrollment ID: I20051205000112 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Linda R Alexander |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689746679 PECOS PAC ID: 9335160985 Enrollment ID: I20051212000481 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elise Newman |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1659326098 PECOS PAC ID: 8224059233 Enrollment ID: I20051216000691 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Geoffrey M Wilson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1336185438 PECOS PAC ID: 3870493786 Enrollment ID: I20051219000124 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lori Siegal |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376656561 PECOS PAC ID: 2062434095 Enrollment ID: I20051219000839 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jon D Prulhiere |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700857174 PECOS PAC ID: 8123040888 Enrollment ID: I20051221000727 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Donna L Hammar |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427006576 PECOS PAC ID: 4688696396 Enrollment ID: I20051222000097 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cameron J Cover |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1609806785 PECOS PAC ID: 2668494121 Enrollment ID: I20051227000398 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brent P Kimberly |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1164462784 PECOS PAC ID: 0446272785 Enrollment ID: I20051229000527 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gunjeet K Samagh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700830981 PECOS PAC ID: 4183692908 Enrollment ID: I20060109000925 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rima Chamie |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316993801 PECOS PAC ID: 4486677929 Enrollment ID: I20060110001005 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard T Warren |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134151822 PECOS PAC ID: 9638193725 Enrollment ID: I20060117000052 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nancy K Moreland |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427088368 PECOS PAC ID: 2365466810 Enrollment ID: I20060123001000 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Janice P Miller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194803718 PECOS PAC ID: 3678594785 Enrollment ID: I20060123001012 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carlos D Sanchez |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1649355678 PECOS PAC ID: 9234153537 Enrollment ID: I20060125000162 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nina L Bergquam |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558301259 PECOS PAC ID: 0345254413 Enrollment ID: I20060127000132 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher J Zaugra |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1871580134 PECOS PAC ID: 0648261263 Enrollment ID: I20060207000811 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David G Silvestre |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831153196 PECOS PAC ID: 0648286062 Enrollment ID: I20060222000548 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ruth Janan Markee |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1821171018 PECOS PAC ID: 2567470032 Enrollment ID: I20060324000109 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Navin N Nayak |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063467181 PECOS PAC ID: 5799795035 Enrollment ID: I20060501000527 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alice C Nayak |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013962513 PECOS PAC ID: 5193735439 Enrollment ID: I20060501000562 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wayne Lawrence Strauss |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1033164389 PECOS PAC ID: 6305892779 Enrollment ID: I20060526000106 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason R Wollmuth |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1164498499 PECOS PAC ID: 1951312255 Enrollment ID: I20060530000217 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tyler Justin Gluckman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1790749422 PECOS PAC ID: 2466464862 Enrollment ID: I20060630000075 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James G Beckerman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1487697488 PECOS PAC ID: 4789630385 Enrollment ID: I20060807000363 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia Shaff Chin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144235656 PECOS PAC ID: 3173520715 Enrollment ID: I20061025000043 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sharon J Hammond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821009606 PECOS PAC ID: 1254338668 Enrollment ID: I20061027000222 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cheri N Oellrich |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851402481 PECOS PAC ID: 3274530357 Enrollment ID: I20061102000371 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Linda I Cruz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1396758512 PECOS PAC ID: 9638177439 Enrollment ID: I20061109000432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa Yao |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1588632202 PECOS PAC ID: 7911961180 Enrollment ID: I20061122000157 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer O'neil Griffith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558372151 PECOS PAC ID: 2365440336 Enrollment ID: I20061130000007 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chandra Shekhar Ojha |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942236559 PECOS PAC ID: 7719986512 Enrollment ID: I20061205000192 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Noelle S Lefitz |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1548362205 PECOS PAC ID: 5496755829 Enrollment ID: I20070108000447 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew J Breeze |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1083655609 PECOS PAC ID: 9335140342 Enrollment ID: I20070117000550 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carmela C Pajarillo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447323878 PECOS PAC ID: 8820099872 Enrollment ID: I20070118000328 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ellen E Lairson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700994225 PECOS PAC ID: 6507842523 Enrollment ID: I20070118000372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin J Grainger |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194889808 PECOS PAC ID: 1456301688 Enrollment ID: I20070119000033 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cornelia C Taylor |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1164593026 PECOS PAC ID: 0749255347 Enrollment ID: I20070119000068 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeremy Swindle |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053381889 PECOS PAC ID: 8921027285 Enrollment ID: I20070123000040 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vitalie D Lupu |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1609837913 PECOS PAC ID: 5092716753 Enrollment ID: I20070123000341 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lori F Gluck |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1225000334 PECOS PAC ID: 3779546874 Enrollment ID: I20070129000611 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven J Riley |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1073625703 PECOS PAC ID: 2668474677 Enrollment ID: I20070205000188 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael A Waddick |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467468132 PECOS PAC ID: 6608878095 Enrollment ID: I20070214000179 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hsiao Chi D Wu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194713313 PECOS PAC ID: 0244232635 Enrollment ID: I20070214000183 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alicia M Ross |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1811053911 PECOS PAC ID: 4789686189 Enrollment ID: I20070214000258 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly J Herder |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1811975741 PECOS PAC ID: 7012019318 Enrollment ID: I20070216000194 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marc B Carey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659311686 PECOS PAC ID: 2769584622 Enrollment ID: I20070222000770 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa L Federspiel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881676641 PECOS PAC ID: 7214937309 Enrollment ID: I20070224000093 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elroy Y Jan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1134212814 PECOS PAC ID: 4587766332 Enrollment ID: I20070225000001 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole L Bishop-perdue |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1275641060 PECOS PAC ID: 5496857245 Enrollment ID: I20070225000002 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen M Mitchell |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1164521654 PECOS PAC ID: 1355342353 Enrollment ID: I20070227000452 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth A Stephens |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1871509364 PECOS PAC ID: 4587766027 Enrollment ID: I20070301000253 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shannon E Jackson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558301168 PECOS PAC ID: 0446352827 Enrollment ID: I20070305000236 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kusum B Asudani |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1104852680 PECOS PAC ID: 8224131461 Enrollment ID: I20070308000595 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly K Rodda |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528054384 PECOS PAC ID: 7618070707 Enrollment ID: I20070309000398 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven P Mcnally |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376635532 PECOS PAC ID: 9739282799 Enrollment ID: I20070312000391 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian J George-mayer |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1790733962 PECOS PAC ID: 4981709698 Enrollment ID: I20070424000627 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leslie Cody |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114008935 PECOS PAC ID: 2466558200 Enrollment ID: I20070510000496 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wilbert R Jones |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1437144078 PECOS PAC ID: 7719084334 Enrollment ID: I20070516000260 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward H Rothberger |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1356307870 PECOS PAC ID: 0446276455 Enrollment ID: I20070523000291 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary A Thomason |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427019322 PECOS PAC ID: 5496854440 Enrollment ID: I20070615000586 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dennis C Tan |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1457577983 PECOS PAC ID: 2860591732 Enrollment ID: I20070619000425 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason Stone |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1720290489 PECOS PAC ID: 1850361775 Enrollment ID: I20070702000103 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elke P Lowenkopf |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1548323009 PECOS PAC ID: 8921108093 Enrollment ID: I20070703000451 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer E Marfori |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1407802143 PECOS PAC ID: 0042310393 Enrollment ID: I20070716000397 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barry M Newman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1881668978 PECOS PAC ID: 7911008867 Enrollment ID: I20070723000681 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathan D Magaret |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1932284536 PECOS PAC ID: 7012018567 Enrollment ID: I20070727000164 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Todd R Merrick |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1114123700 PECOS PAC ID: 4486755162 Enrollment ID: I20070731000077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Willscott E Naugler |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1689698342 PECOS PAC ID: 6507868767 Enrollment ID: I20070803000179 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shauna L Ensminger |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619960002 PECOS PAC ID: 6800863283 Enrollment ID: I20070806000662 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura J Kim |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1083737266 PECOS PAC ID: 5193817468 Enrollment ID: I20070816000829 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer A Rose |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1801822697 PECOS PAC ID: 8325042070 Enrollment ID: I20070817000106 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher M Berberian |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1710185087 PECOS PAC ID: 0244322022 Enrollment ID: I20070824000225 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evagelia Baros |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003019340 PECOS PAC ID: 2860584653 Enrollment ID: I20070824000257 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Man M Tran |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558384313 PECOS PAC ID: 2668565607 Enrollment ID: I20070906000539 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michelle L Schoepflin Sanders |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891996765 PECOS PAC ID: 9335232313 Enrollment ID: I20070907000000 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tzann T Fang |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1275609349 PECOS PAC ID: 8022101906 Enrollment ID: I20070908000133 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erin R Shawn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518099241 PECOS PAC ID: 9436243847 Enrollment ID: I20070917000159 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samantha R Adkins |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790905164 PECOS PAC ID: 7214021641 Enrollment ID: I20070917000275 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Deani K Iversen |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1730302076 PECOS PAC ID: 4284728643 Enrollment ID: I20070917000564 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca M Cleeton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972710556 PECOS PAC ID: 2961596291 Enrollment ID: I20070918000359 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John R Steeh |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1447359914 PECOS PAC ID: 5890880728 Enrollment ID: I20071005000788 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jagdish R Ragade |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1477542108 PECOS PAC ID: 3072510866 Enrollment ID: I20071009000593 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erin J Allen |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1346344611 PECOS PAC ID: 2860491933 Enrollment ID: I20071011000580 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauri J Winther |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669691119 PECOS PAC ID: 3577659184 Enrollment ID: I20071012000110 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David L Hays |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1396765087 PECOS PAC ID: 0345267720 Enrollment ID: I20071015000051 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine L Stock |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1316060536 PECOS PAC ID: 1658467949 Enrollment ID: I20071018000042 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maureen A Sprague |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1578654059 PECOS PAC ID: 6709972698 Enrollment ID: I20071024000147 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashkan N Babaie |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1770780215 PECOS PAC ID: 9830186287 Enrollment ID: I20071026000120 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David K Moon |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1609872753 PECOS PAC ID: 4981607710 Enrollment ID: I20071113000522 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joseph M Obadiah |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1699818120 PECOS PAC ID: 8729178439 Enrollment ID: I20071219000185 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sonel P Patel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528089026 PECOS PAC ID: 0143295261 Enrollment ID: I20071220000256 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yale Y Liang |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982664637 PECOS PAC ID: 1052353828 Enrollment ID: I20080108000881 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yolanda C Domond |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225161243 PECOS PAC ID: 7315027802 Enrollment ID: I20080109000774 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ann G Scott |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871678565 PECOS PAC ID: 5092896225 Enrollment ID: I20080114000762 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dalika G Crawford |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1508972597 PECOS PAC ID: 2860573961 Enrollment ID: I20080115000392 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily Hitchcock |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1710915202 PECOS PAC ID: 2961583463 Enrollment ID: I20080122000455 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Claudia S Leonard |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1477588143 PECOS PAC ID: 2365523883 Enrollment ID: I20080122000569 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexander D Schafir |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629093059 PECOS PAC ID: 6709967227 Enrollment ID: I20080122000580 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer L Lycette |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1801847355 PECOS PAC ID: 1557372752 Enrollment ID: I20080128000475 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stanley L Cohan |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1972788644 PECOS PAC ID: 8820170731 Enrollment ID: I20080131000276 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony David Marrone |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1518919851 PECOS PAC ID: 8921071424 Enrollment ID: I20080201000033 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy L Gerhard |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326233065 PECOS PAC ID: 4688756224 Enrollment ID: I20080204000767 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stacy K Lewis |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1124021753 PECOS PAC ID: 6901848597 Enrollment ID: I20080214000107 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Casey E Ferguson |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1447375233 PECOS PAC ID: 1759373319 Enrollment ID: I20080219000510 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brendan Cargill Carroll |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1669472775 PECOS PAC ID: 3678656444 Enrollment ID: I20080303000367 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Darren B Lewis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1699847731 PECOS PAC ID: 0143305904 Enrollment ID: I20080304000785 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Saramati J Krishna |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1548445497 PECOS PAC ID: 7911082284 Enrollment ID: I20080311000353 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Xiang-hong Song |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1043327109 PECOS PAC ID: 3375628571 Enrollment ID: I20080312000416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nagendra R Tirumali |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1669565230 PECOS PAC ID: 2062598998 Enrollment ID: I20080318000566 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tracy Woodson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1922112051 PECOS PAC ID: 8921184714 Enrollment ID: I20080319000268 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Harriet R Stosur |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1386739753 PECOS PAC ID: 5092891226 Enrollment ID: I20080327000478 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kyle E Smoot |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1124170063 PECOS PAC ID: 1153397146 Enrollment ID: I20080410000568 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leila H Mesch |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1215041124 PECOS PAC ID: 1951489335 Enrollment ID: I20080425000156 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alan R Burningham |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1578669487 PECOS PAC ID: 7911940838 Enrollment ID: I20080507000244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew C Mcclelland |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1346394954 PECOS PAC ID: 0749359040 Enrollment ID: I20080513000143 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian A Kendall |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1104017052 PECOS PAC ID: 9931278009 Enrollment ID: I20080515000020 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia M Beall |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952573438 PECOS PAC ID: 8426129842 Enrollment ID: I20080612000417 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paula Gerber-gore |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1518156504 PECOS PAC ID: 0143392464 Enrollment ID: I20080702000197 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John T Thiesing |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1225104599 PECOS PAC ID: 7517039654 Enrollment ID: I20080707000026 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Janet C Ruzich |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1508869140 PECOS PAC ID: 5890700280 Enrollment ID: I20080709000204 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert F Quintos |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1750324653 PECOS PAC ID: 5890737886 Enrollment ID: I20080710000300 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Devn Brown |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164683843 PECOS PAC ID: 0244303931 Enrollment ID: I20080714000208 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel Plotinsky |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1003965948 PECOS PAC ID: 1153494810 Enrollment ID: I20080715000130 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christie J Moore |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1891727608 PECOS PAC ID: 1254404932 Enrollment ID: I20080715000202 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren A Cooper |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1497833578 PECOS PAC ID: 2163437021 Enrollment ID: I20080722000774 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Adam A Blomberg |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942491899 PECOS PAC ID: 7517030539 Enrollment ID: I20080723000597 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David L Corman |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1770794901 PECOS PAC ID: 7315010345 Enrollment ID: I20080723000693 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Olga Bendinger |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1871613802 PECOS PAC ID: 6901982016 Enrollment ID: I20080723000848 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel S Graves |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659570190 PECOS PAC ID: 6709959695 Enrollment ID: I20080725000393 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Rahkola |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700044583 PECOS PAC ID: 4284708058 Enrollment ID: I20080729000276 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura L Kuipers |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1902097850 PECOS PAC ID: 1052485737 Enrollment ID: I20080729000400 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alma Draper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285897009 PECOS PAC ID: 6103990742 Enrollment ID: I20080731000133 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Katherine Alvarez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619927944 PECOS PAC ID: 9537148697 Enrollment ID: I20080731000339 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard C Manthey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1639120314 PECOS PAC ID: 4880768217 Enrollment ID: I20080804000319 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah J Lipton |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1023229812 PECOS PAC ID: 5698840072 Enrollment ID: I20080819000958 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory M Eilers |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1134323843 PECOS PAC ID: 1355416660 Enrollment ID: I20080821000344 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alison K Conlin |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1841460193 PECOS PAC ID: 4385719541 Enrollment ID: I20080822000145 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lori L Lingle Elling |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194858944 PECOS PAC ID: 7315013059 Enrollment ID: I20080904000248 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey Penikas |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1063447043 PECOS PAC ID: 2365459062 Enrollment ID: I20080904000383 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shawn M Morgan |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1477538064 PECOS PAC ID: 8224025325 Enrollment ID: I20080908000330 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joanne T Eddington |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417950015 PECOS PAC ID: 5991710311 Enrollment ID: I20080910000138 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kari Mazur |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1871797340 PECOS PAC ID: 7416023692 Enrollment ID: I20080912000135 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chunfeng Zhang |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1972773786 PECOS PAC ID: 3577639756 Enrollment ID: I20080912000155 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aileen H Kim |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255360657 PECOS PAC ID: 5395812283 Enrollment ID: I20080918000209 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy Margarete Dechet |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1508031832 PECOS PAC ID: 3678640588 Enrollment ID: I20080918000377 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick J Gaston |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1811103682 PECOS PAC ID: 0345317103 Enrollment ID: I20080919000103 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lesley L Liu |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1487819959 PECOS PAC ID: 0840367603 Enrollment ID: I20080919000140 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jean D Lee |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1346450319 PECOS PAC ID: 0648379362 Enrollment ID: I20080922000287 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David K Solondz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1689896599 PECOS PAC ID: 7315015070 Enrollment ID: I20081008000007 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wendy Y Laborie |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861599664 PECOS PAC ID: 1355325846 Enrollment ID: I20081017000390 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory Robert Flick |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1417991969 PECOS PAC ID: 3870525264 Enrollment ID: I20081113000712 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey P Pavelka |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447218318 PECOS PAC ID: 8628086378 Enrollment ID: I20081124000225 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory T Jorgensen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417119843 PECOS PAC ID: 5890856264 Enrollment ID: I20081203000510 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anna G Spann |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1316139447 PECOS PAC ID: 6305907361 Enrollment ID: I20081209000469 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Crispin H Davies |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1982610481 PECOS PAC ID: 9032270095 Enrollment ID: I20081209000471 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robin Y Grattan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205951530 PECOS PAC ID: 0042371973 Enrollment ID: I20081210000244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew J Mills |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1710187489 PECOS PAC ID: 8426110370 Enrollment ID: I20081231000144 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrea B Roast |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891878070 PECOS PAC ID: 9032272828 Enrollment ID: I20090105000430 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark R Rosenberg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922181106 PECOS PAC ID: 0446313084 Enrollment ID: I20090108000485 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Meera Jain |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1083797260 PECOS PAC ID: 0941363311 Enrollment ID: I20090112000165 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mari Kai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942383120 PECOS PAC ID: 2365505740 Enrollment ID: I20090112000217 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathleen M Thurman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821242330 PECOS PAC ID: 8022173731 Enrollment ID: I20090212000458 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michelle C Hall |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457337859 PECOS PAC ID: 7911997895 Enrollment ID: I20090219000479 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark S Puscas |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1982717583 PECOS PAC ID: 9931265360 Enrollment ID: I20090310000049 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Theodore J Lowenkopf |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1629059407 PECOS PAC ID: 8921165606 Enrollment ID: I20090324000675 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Diana Gill |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1386893444 PECOS PAC ID: 9335296912 Enrollment ID: I20090416000777 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hanny A Tan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881770501 PECOS PAC ID: 7315998077 Enrollment ID: I20090420000606 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Justin S Jin |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1710054218 PECOS PAC ID: 2567510308 Enrollment ID: I20090504000673 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa M Enger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295983617 PECOS PAC ID: 9436207909 Enrollment ID: I20090512000048 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joel B Williams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932174927 PECOS PAC ID: 4688723349 Enrollment ID: I20090529000069 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Deborah J Murphy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1073588471 PECOS PAC ID: 5092701474 Enrollment ID: I20090601000024 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vincent Torres |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1942334123 PECOS PAC ID: 8820188592 Enrollment ID: I20090603000532 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kori L Anderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043479389 PECOS PAC ID: 6709936180 Enrollment ID: I20090604000614 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine D Brown |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194822965 PECOS PAC ID: 2567512593 Enrollment ID: I20090611000722 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Luis E Scheker |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1740293158 PECOS PAC ID: 7113927237 Enrollment ID: I20090612000416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Virginia C Leslie |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336119288 PECOS PAC ID: 4789657487 Enrollment ID: I20090706000458 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wai L Lee |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1881623254 PECOS PAC ID: 4385797257 Enrollment ID: I20090727000057 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heh Shin R Kwak |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1174715924 PECOS PAC ID: 2466513320 Enrollment ID: I20090728000637 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amit A Barve |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1760667059 PECOS PAC ID: 2567510787 Enrollment ID: I20090729000503 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexi P Zemsky |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1598944928 PECOS PAC ID: 3173677192 Enrollment ID: I20090810000651 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sheryll L Rosario |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811192131 PECOS PAC ID: 9537213517 Enrollment ID: I20090812000764 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vaishali Y Hotanalli |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1902991672 PECOS PAC ID: 3870647654 Enrollment ID: I20090812000889 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark A Gibson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1710122106 PECOS PAC ID: 0648324194 Enrollment ID: I20090818000338 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Colby E Harrison |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1366604589 PECOS PAC ID: 9436203684 Enrollment ID: I20090821000530 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rosario P Bonafede |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1730125667 PECOS PAC ID: 7214081462 Enrollment ID: I20090821000570 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katja F Daoud |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1316977309 PECOS PAC ID: 5294889457 Enrollment ID: I20090821000597 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel B Mccabe |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1922275031 PECOS PAC ID: 3072667112 Enrollment ID: I20090824000649 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Allen K Moore |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1174662167 PECOS PAC ID: 5496800526 Enrollment ID: I20090826000116 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ethan Korngold |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1568452738 PECOS PAC ID: 0345248464 Enrollment ID: I20090826000937 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jacob Abraham |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1548223381 PECOS PAC ID: 6204863541 Enrollment ID: I20090826000942 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jay B Ham |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1760659627 PECOS PAC ID: 7113072943 Enrollment ID: I20090831000689 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Staci J Eskesen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1689629628 PECOS PAC ID: 4385656552 Enrollment ID: I20090904000539 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tom Chau |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629259916 PECOS PAC ID: 1850477019 Enrollment ID: I20090909000673 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stanley J Cyran |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1083653653 PECOS PAC ID: 6709932627 Enrollment ID: I20090918000009 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert Dong Kim |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1780620096 PECOS PAC ID: 5597783738 Enrollment ID: I20090924000569 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Quinn R Emerson |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1861669723 PECOS PAC ID: 2264588755 Enrollment ID: I20090924000701 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Fareha A Nawaz |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1770702839 PECOS PAC ID: 8628114717 Enrollment ID: I20091002000313 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paula Wagenbach |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1497828875 PECOS PAC ID: 8729124524 Enrollment ID: I20091008000362 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark D Dunn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841496023 PECOS PAC ID: 0840336541 Enrollment ID: I20091012000031 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laurence Colman |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1225106032 PECOS PAC ID: 4183760663 Enrollment ID: I20091014000427 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sophana Karnchanasorn |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1710165303 PECOS PAC ID: 6800933276 Enrollment ID: I20091019000102 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rhonda C Tierney |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447250360 PECOS PAC ID: 9032256086 Enrollment ID: I20091022000680 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura L Loertscher |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164528865 PECOS PAC ID: 0446256655 Enrollment ID: I20091027000503 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dong L Ji |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033273784 PECOS PAC ID: 2365431475 Enrollment ID: I20091029000763 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lesley N Bobek |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1922202787 PECOS PAC ID: 0244377802 Enrollment ID: I20091030000277 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tula Top |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1346432721 PECOS PAC ID: 0840337473 Enrollment ID: I20091104000689 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbara Js Esselink |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548451479 PECOS PAC ID: 0446398762 Enrollment ID: I20091106000286 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth Thornton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942432794 PECOS PAC ID: 8325186653 Enrollment ID: I20091106000397 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ellen Priscilla S Bautista |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174744395 PECOS PAC ID: 9436299823 Enrollment ID: I20091215000686 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather E Prouty |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1538371620 PECOS PAC ID: 2668539784 Enrollment ID: I20091228000094 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas J Croy |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1770579237 PECOS PAC ID: 4183765878 Enrollment ID: I20091231000432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin J Jamison |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1003811373 PECOS PAC ID: 2365479151 Enrollment ID: I20100107000639 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew G Barnes |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1295979805 PECOS PAC ID: 0547301533 Enrollment ID: I20100113000480 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alison Y Ma |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1609083237 PECOS PAC ID: 5698828226 Enrollment ID: I20100121000733 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cheryl C Pierson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063520609 PECOS PAC ID: 7315091618 Enrollment ID: I20100201000751 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily Lynn |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1548322209 PECOS PAC ID: 4385713320 Enrollment ID: I20100217000880 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aaron B Schoenkerman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1487748836 PECOS PAC ID: 8224017447 Enrollment ID: I20100218000442 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Namrata J Ragade |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1518996198 PECOS PAC ID: 1759478498 Enrollment ID: I20100304000963 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hyun S Suh |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1952450561 PECOS PAC ID: 1153403035 Enrollment ID: I20100309000754 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Darren L Gillette |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1326068891 PECOS PAC ID: 2365473238 Enrollment ID: I20100315000111 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laurie Chern |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457385114 PECOS PAC ID: 6204961311 Enrollment ID: I20100315000643 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carol M Suzuki |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1427068410 PECOS PAC ID: 9830224872 Enrollment ID: I20100317000357 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samson J Spilk Wall |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1619169109 PECOS PAC ID: 4183750532 Enrollment ID: I20100325000151 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kendra J Watson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760637920 PECOS PAC ID: 8729114046 Enrollment ID: I20100325000885 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa A Thum |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1396761482 PECOS PAC ID: 4880721257 Enrollment ID: I20100416000626 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth A Reindl |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1730112517 PECOS PAC ID: 8123155595 Enrollment ID: I20100416000654 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Victorya V Khary |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1588690820 PECOS PAC ID: 8527195890 Enrollment ID: I20100416000729 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Linh D Dao |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518997584 PECOS PAC ID: 9537296751 Enrollment ID: I20100420000871 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard Tsai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558387555 PECOS PAC ID: 4789711904 Enrollment ID: I20100420000903 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristin Stevens |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1689690737 PECOS PAC ID: 5890822027 Enrollment ID: I20100420001009 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dianne C Eardley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740210434 PECOS PAC ID: 1951438191 Enrollment ID: I20100420001044 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory P Garcia |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922036219 PECOS PAC ID: 4981731981 Enrollment ID: I20100422001174 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caroline Reay |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447283205 PECOS PAC ID: 6507993250 Enrollment ID: I20100428000854 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Douglas R Niehus |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144250085 PECOS PAC ID: 1658408323 Enrollment ID: I20100429000059 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard L Hsu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174552491 PECOS PAC ID: 6901933670 Enrollment ID: I20100429000088 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marianne C Parshley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760415376 PECOS PAC ID: 1052448727 Enrollment ID: I20100429000120 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Linda M Hungerford |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902832363 PECOS PAC ID: 0042347726 Enrollment ID: I20100429000149 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa M Paul |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578594511 PECOS PAC ID: 6305973082 Enrollment ID: I20100429000172 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Janet E Patin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1689605776 PECOS PAC ID: 9537058797 Enrollment ID: I20100504000455 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher S Ritchie |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487673190 PECOS PAC ID: 3274661525 Enrollment ID: I20100507000380 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan J Barton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265666549 PECOS PAC ID: 6901934181 Enrollment ID: I20100507000793 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charmika T Schuster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902133176 PECOS PAC ID: 5799813762 Enrollment ID: I20100512000617 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dominique Greco |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558469510 PECOS PAC ID: 6709914724 Enrollment ID: I20100512001057 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lee A Salsburg |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720077696 PECOS PAC ID: 3577554450 Enrollment ID: I20100517000748 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sheeten B Doshi |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1154307478 PECOS PAC ID: 4284679416 Enrollment ID: I20100520000180 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica K Aaker |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1780778795 PECOS PAC ID: 3971633769 Enrollment ID: I20100604000315 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shirley A Malcolm |
|---|---|
| Provider Type | Practitioner - Osteopathic Manipulative Medicine |
| Provider Identifiers | NPI Number: 1316951510 PECOS PAC ID: 2062542665 Enrollment ID: I20100608000681 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ranjana S Nathan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1588690127 PECOS PAC ID: 1759411275 Enrollment ID: I20100610000158 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susan D Payne |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1508891805 PECOS PAC ID: 0143351973 Enrollment ID: I20100623000413 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samuel J Fellin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1265463996 PECOS PAC ID: 1153452925 Enrollment ID: I20100623000809 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew H Taylor |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1134239197 PECOS PAC ID: 9234260548 Enrollment ID: I20100630000849 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather M Pfeiffer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780781740 PECOS PAC ID: 0042217366 Enrollment ID: I20100702000199 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David C Childers |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043401029 PECOS PAC ID: 3274665062 Enrollment ID: I20100714000285 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeff A Campbell |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1073704052 PECOS PAC ID: 8426180217 Enrollment ID: I20100714000318 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael E Carroll |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194752857 PECOS PAC ID: 3779615562 Enrollment ID: I20100714000345 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Poombavai O Nagappan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043246689 PECOS PAC ID: 2668504903 Enrollment ID: I20100721000906 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven Scott Andersen |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1184606295 PECOS PAC ID: 9335204031 Enrollment ID: I20100812000058 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sunita M Deshmukh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730133679 PECOS PAC ID: 0446384838 Enrollment ID: I20100820000713 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Darlene Joyce Dodson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1013974559 PECOS PAC ID: 4082738760 Enrollment ID: I20100901000920 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Liberato Mukul |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1932129491 PECOS PAC ID: 7416923339 Enrollment ID: I20100903000165 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James M Martinson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1144232554 PECOS PAC ID: 5294859740 Enrollment ID: I20100903000959 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eli K Klovee-smith |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1619153582 PECOS PAC ID: 6204951619 Enrollment ID: I20100908000973 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Promporn Wichienkuer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598978272 PECOS PAC ID: 2961527346 Enrollment ID: I20100909000548 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelly S Perlewitz |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1508086067 PECOS PAC ID: 1951426683 Enrollment ID: I20100917000314 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anika Denali-luengo |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871774281 PECOS PAC ID: 6103941851 Enrollment ID: I20100917000531 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia B Toub |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1104095421 PECOS PAC ID: 8123144524 Enrollment ID: I20100922001147 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eric I Friedman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1932267333 PECOS PAC ID: 4284750399 Enrollment ID: I20100927000673 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bryce S Milligan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1285893941 PECOS PAC ID: 6406972330 Enrollment ID: I20100928000916 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elise D Anderson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1972764777 PECOS PAC ID: 9931225794 Enrollment ID: I20100929000774 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chirag R Patel |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1720020951 PECOS PAC ID: 9436175205 Enrollment ID: I20101005001338 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather L Whetstone |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770788176 PECOS PAC ID: 3173715091 Enrollment ID: I20101011001147 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Annette Schweiger Fischer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356405690 PECOS PAC ID: 1456544915 Enrollment ID: I20101018000551 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia L Torres |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013183151 PECOS PAC ID: 7618160185 Enrollment ID: I20101018000582 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jill M Gelow |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1285741843 PECOS PAC ID: 2860685278 Enrollment ID: I20101018001291 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John O Evered |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1982680997 PECOS PAC ID: 0941364079 Enrollment ID: I20101020000709 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrea Orfanakis |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1861549669 PECOS PAC ID: 0840484523 Enrollment ID: I20101027000886 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anne M Houff |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1013116565 PECOS PAC ID: 2062606304 Enrollment ID: I20101101000984 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James H Imatani |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1891707766 PECOS PAC ID: 5799979944 Enrollment ID: I20101101001266 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anh Q Nguyen |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1679894877 PECOS PAC ID: 3678767845 Enrollment ID: I20101101001590 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William C Chapin |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1083653679 PECOS PAC ID: 6406040682 Enrollment ID: I20101102000090 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evelyn S Kim |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1275618878 PECOS PAC ID: 6901090711 Enrollment ID: I20101104001335 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole S Trajano |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518906114 PECOS PAC ID: 3779777594 Enrollment ID: I20101104001534 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yuriko Lee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669786661 PECOS PAC ID: 9830384502 Enrollment ID: I20101109000208 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James Thompson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1871663245 PECOS PAC ID: 8426243320 Enrollment ID: I20101117000103 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Allison A Jones |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811200066 PECOS PAC ID: 8426244369 Enrollment ID: I20101118000301 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Roxanne M Payne |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295040905 PECOS PAC ID: 6800082223 Enrollment ID: I20101124001070 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heena Satish Doshi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508809781 PECOS PAC ID: 8527254853 Enrollment ID: I20101129000032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kurt Duffens |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1013003045 PECOS PAC ID: 4880880186 Enrollment ID: I20101129001005 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathaniel S Brigham |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1851362578 PECOS PAC ID: 5991991143 Enrollment ID: I20101130000525 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Philippa Holly Alexandra Newell |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1508028739 PECOS PAC ID: 4284821208 Enrollment ID: I20101202001240 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Colleen M Casey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154642700 PECOS PAC ID: 3173710746 Enrollment ID: I20101208000549 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ellen L Andrae |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1427248202 PECOS PAC ID: 0345437539 Enrollment ID: I20101214000989 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kenneth A Ensroth |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1770599185 PECOS PAC ID: 8426246778 Enrollment ID: I20101230000604 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Martha S Roellig |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1316914807 PECOS PAC ID: 9638366792 Enrollment ID: I20110106000777 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Clyde Finch |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598884033 PECOS PAC ID: 4284732488 Enrollment ID: I20110107000752 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shirley A. Fox |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1437131984 PECOS PAC ID: 9032308416 Enrollment ID: I20110117000229 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert Willis Morse |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1174555312 PECOS PAC ID: 0941192892 Enrollment ID: I20110118000320 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John F Zurasky |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1255337572 PECOS PAC ID: 9234109802 Enrollment ID: I20110118000751 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susanne K Bobenrieth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871577742 PECOS PAC ID: 2365438744 Enrollment ID: I20110121001016 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rodney J Reid |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1417110149 PECOS PAC ID: 9335320563 Enrollment ID: I20110222000548 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian T Little |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912987009 PECOS PAC ID: 9436142437 Enrollment ID: I20110321000779 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tanya M Scheibe Mirek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578868022 PECOS PAC ID: 0749463255 Enrollment ID: I20110321001014 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Diane K Clark |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881863488 PECOS PAC ID: 3274660493 Enrollment ID: I20110325000419 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas Wimmer |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1083725097 PECOS PAC ID: 7517964497 Enrollment ID: I20110429000115 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Fareeha Majeed |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134325541 PECOS PAC ID: 2567531403 Enrollment ID: I20110429000209 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charlotte C Ott |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1073538450 PECOS PAC ID: 7315941531 Enrollment ID: I20110510000359 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jun Ma |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417266354 PECOS PAC ID: 0749466019 Enrollment ID: I20110520000652 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James S Chong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821245788 PECOS PAC ID: 8527246131 Enrollment ID: I20110630000503 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alex Jenkins |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1306877535 PECOS PAC ID: 0143318642 Enrollment ID: I20110701000065 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lianne Liang-jung Lin |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1497910210 PECOS PAC ID: 1355519950 Enrollment ID: I20110727000000 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael J Goldstein |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1265693287 PECOS PAC ID: 4082882683 Enrollment ID: I20110727000004 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory M Stroup |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1053532564 PECOS PAC ID: 1254509854 Enrollment ID: I20110727000014 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeremy R Krueger |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1750543195 PECOS PAC ID: 3870761489 Enrollment ID: I20110727000049 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nikhil Batra |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205091576 PECOS PAC ID: 6305015199 Enrollment ID: I20110811000871 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Holly Milne Hofkamp |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1043402712 PECOS PAC ID: 8628115763 Enrollment ID: I20110812000442 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel E Emery |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1770748584 PECOS PAC ID: 7517136070 Enrollment ID: I20110818000139 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tricia T James |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1205097235 PECOS PAC ID: 1557530029 Enrollment ID: I20110818000206 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charles Thayer White |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740485432 PECOS PAC ID: 9739359258 Enrollment ID: I20110818000836 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard B Cook |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1184869448 PECOS PAC ID: 5496925794 Enrollment ID: I20110824000244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aneet J Deo |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013107556 PECOS PAC ID: 2466622592 Enrollment ID: I20110829000694 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jared A Shipley |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1194933770 PECOS PAC ID: 4284820275 Enrollment ID: I20110906000167 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mubeen A Jafri |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1245433184 PECOS PAC ID: 8022289511 Enrollment ID: I20110913000563 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lian R Shaw |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1154379576 PECOS PAC ID: 6002807724 Enrollment ID: I20110921000884 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Renata Yang |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1689817199 PECOS PAC ID: 3375714074 Enrollment ID: I20110928000565 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin L Calvert |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316195704 PECOS PAC ID: 9931370624 Enrollment ID: I20110929000659 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Swati S Kakodkar |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578632469 PECOS PAC ID: 6709972490 Enrollment ID: I20110930000213 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick K Lew |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1598961070 PECOS PAC ID: 6305018987 Enrollment ID: I20111003000564 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa N Moffitt |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1346307709 PECOS PAC ID: 0547432171 Enrollment ID: I20111004000379 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Karen E Minzer Conzetti |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1508010372 PECOS PAC ID: 8820260359 Enrollment ID: I20111005000768 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eileen K Mccarty |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1285879676 PECOS PAC ID: 2264604669 Enrollment ID: I20111006000762 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shane O Rogosin |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1447451794 PECOS PAC ID: 8820260268 Enrollment ID: I20111007000429 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David J Tovey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1932276961 PECOS PAC ID: 7113952623 Enrollment ID: I20111010000331 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathleen Sher |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1215173836 PECOS PAC ID: 6002088259 Enrollment ID: I20111011000776 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ami D Kapadia |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366565509 PECOS PAC ID: 2961579909 Enrollment ID: I20111012000561 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy S Frankel |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1427293208 PECOS PAC ID: 2163694068 Enrollment ID: I20111019000639 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie B Mentch |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730476250 PECOS PAC ID: 4284806084 Enrollment ID: I20111019000863 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shaik I Basha |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1578712378 PECOS PAC ID: 0244403723 Enrollment ID: I20111027000862 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bertha A Kao |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1912916271 PECOS PAC ID: 9335133768 Enrollment ID: I20111110000497 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Peter J Taylor |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1124207436 PECOS PAC ID: 5092989103 Enrollment ID: I20111129000244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen Barri Heitner |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1508079419 PECOS PAC ID: 6709925829 Enrollment ID: I20111130000463 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julianne F Brock |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639450315 PECOS PAC ID: 1850566597 Enrollment ID: I20111208000459 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Olivia Kamayangi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437312766 PECOS PAC ID: 7618155714 Enrollment ID: I20111212000589 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Karla A Mcgee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457597072 PECOS PAC ID: 2264608611 Enrollment ID: I20120105000838 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Crystal S Query |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750546461 PECOS PAC ID: 1153597463 Enrollment ID: I20120106000603 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Roberta C Bentson Royal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679626964 PECOS PAC ID: 4183890437 Enrollment ID: I20120109000206 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine M Kemp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215158639 PECOS PAC ID: 3274677018 Enrollment ID: I20120116000095 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jonathan L Vinson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003836487 PECOS PAC ID: 9638113533 Enrollment ID: I20120124000982 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward J Chaplain |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275559940 PECOS PAC ID: 7113955782 Enrollment ID: I20120124000985 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ronald J Dworkin |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1154327997 PECOS PAC ID: 7810038411 Enrollment ID: I20120220001017 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maxine E Bauer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1497749345 PECOS PAC ID: 6709968829 Enrollment ID: I20120319000421 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nancy M Grant |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1659365260 PECOS PAC ID: 7618059734 Enrollment ID: I20120319000442 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Briana J Mejia |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063678720 PECOS PAC ID: 0648317958 Enrollment ID: I20120319000551 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Fortune L Lallande |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1962508499 PECOS PAC ID: 4284895715 Enrollment ID: I20120410000712 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca B Rawson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548573579 PECOS PAC ID: 7517120058 Enrollment ID: I20120521000649 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian Anthony Wheeler |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1962645028 PECOS PAC ID: 0547423907 Enrollment ID: I20120522000924 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amit C Kansara |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1104093665 PECOS PAC ID: 4486817541 Enrollment ID: I20120530000096 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hyrum F Durtschi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841336633 PECOS PAC ID: 0648433706 Enrollment ID: I20120530000119 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily J Puukka Clark |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174759849 PECOS PAC ID: 6901069061 Enrollment ID: I20120530000134 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tollie M Bohl |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417245358 PECOS PAC ID: 7315102084 Enrollment ID: I20120702000191 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah J Ridley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689683484 PECOS PAC ID: 0749285336 Enrollment ID: I20120702000437 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason Charles Wells |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1497791610 PECOS PAC ID: 9436218823 Enrollment ID: I20120710000357 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joanna O Leary |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1417101999 PECOS PAC ID: 6608032735 Enrollment ID: I20120718000329 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Terry Joan Wrobel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831377175 PECOS PAC ID: 0547247629 Enrollment ID: I20120725000756 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jean Y Rim |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1518097963 PECOS PAC ID: 8123284437 Enrollment ID: I20120731000425 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gabriel A Hyder |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1992947329 PECOS PAC ID: 4183880404 Enrollment ID: I20120731000478 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole Hainley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609172006 PECOS PAC ID: 7911153077 Enrollment ID: I20120807000079 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Janelle D Yutzie |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1720200025 PECOS PAC ID: 1850468901 Enrollment ID: I20120809000345 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbra Fisher |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1679695050 PECOS PAC ID: 4486754645 Enrollment ID: I20120816000981 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Denise M Janetos |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467497073 PECOS PAC ID: 9335121672 Enrollment ID: I20120820001208 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lohith V Reddy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043442007 PECOS PAC ID: 0840447967 Enrollment ID: I20120824000427 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas B Nelson |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1063646255 PECOS PAC ID: 8224285192 Enrollment ID: I20120828000659 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin J Woolf |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1265580054 PECOS PAC ID: 6709971112 Enrollment ID: I20120829000476 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Archit C Bhatt |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1750574547 PECOS PAC ID: 0648394155 Enrollment ID: I20120904000561 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashley E Hart |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1609000942 PECOS PAC ID: 8820245483 Enrollment ID: I20120904000585 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sekou C Ford |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538138276 PECOS PAC ID: 3476700956 Enrollment ID: I20120906000419 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Cheng |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811194525 PECOS PAC ID: 2062660590 Enrollment ID: I20120907000173 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chandra M Oleksiewicz |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1811107832 PECOS PAC ID: 9335205111 Enrollment ID: I20120921000758 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael A Ohara |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1699900712 PECOS PAC ID: 9739337437 Enrollment ID: I20120921000785 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine L Johnson |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1508070046 PECOS PAC ID: 9335212133 Enrollment ID: I20120921000793 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesus A Moreno |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1710113386 PECOS PAC ID: 7719135417 Enrollment ID: I20120921000797 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine H Ching |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1245551290 PECOS PAC ID: 8325296932 Enrollment ID: I20120924000152 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Scott C Brancato |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1184849762 PECOS PAC ID: 9931358629 Enrollment ID: I20121015000084 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah R Oller |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1982619565 PECOS PAC ID: 0941451769 Enrollment ID: I20121103000001 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dorian Ramirez |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1609074020 PECOS PAC ID: 0244317915 Enrollment ID: I20121113000644 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sheri B Prom |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386996999 PECOS PAC ID: 0143471383 Enrollment ID: I20121115000334 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Natalya Balanetskaya |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437405891 PECOS PAC ID: 4082865266 Enrollment ID: I20121116000153 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer M Hill |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1194048264 PECOS PAC ID: 0446401517 Enrollment ID: I20121119000567 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Olivia J Ullrich |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265688600 PECOS PAC ID: 2860543691 Enrollment ID: I20121120000201 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan M Smith |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1710111448 PECOS PAC ID: 3678725173 Enrollment ID: I20121207000423 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rom S Leidner |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1801908702 PECOS PAC ID: 1052339066 Enrollment ID: I20121210000122 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ghazaleh Jafari |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1821258468 PECOS PAC ID: 2961655204 Enrollment ID: I20130116000509 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vanessa Vanderpool |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154555498 PECOS PAC ID: 3173777406 Enrollment ID: I20130213000494 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey A Youker |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669791570 PECOS PAC ID: 6002061165 Enrollment ID: I20130222000033 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chad Robinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336431154 PECOS PAC ID: 4183895105 Enrollment ID: I20130410000124 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erica C Delgado |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922138627 PECOS PAC ID: 1153499736 Enrollment ID: I20130419000315 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jayne E Elken |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104176023 PECOS PAC ID: 7315183159 Enrollment ID: I20130423000233 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian T Pavic |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1972822195 PECOS PAC ID: 1254577869 Enrollment ID: I20130425000569 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura D Milner |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1144560582 PECOS PAC ID: 9234376500 Enrollment ID: I20130503000228 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniela Letz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184785727 PECOS PAC ID: 1355588526 Enrollment ID: I20130507000192 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachael Lien Yeoman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437439528 PECOS PAC ID: 8729226956 Enrollment ID: I20130530000309 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie L Dailey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841434990 PECOS PAC ID: 6709021561 Enrollment ID: I20130603000709 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kashif I K Sherwani |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1952514341 PECOS PAC ID: 1658471727 Enrollment ID: I20130611000668 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hina A Khan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912136011 PECOS PAC ID: 7911155627 Enrollment ID: I20130703000349 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lori M Tam |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1306036108 PECOS PAC ID: 4981844420 Enrollment ID: I20130708000029 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aaron J Chan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1750607594 PECOS PAC ID: 9638319361 Enrollment ID: I20130709000753 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew D Rontal |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1063657328 PECOS PAC ID: 7911150065 Enrollment ID: I20130710000362 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Theodore Allen Foster |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154646610 PECOS PAC ID: 0143466433 Enrollment ID: I20130712000332 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather S Abe |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1265745947 PECOS PAC ID: 1052552163 Enrollment ID: I20130731000694 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andre D Grisham |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1629042122 PECOS PAC ID: 1355325184 Enrollment ID: I20130801000794 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua D Remick |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1861697682 PECOS PAC ID: 2264698695 Enrollment ID: I20130802000124 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa A Hemphill |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801115100 PECOS PAC ID: 4183862303 Enrollment ID: I20130805000283 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John C Robison |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205158128 PECOS PAC ID: 4284762543 Enrollment ID: I20130805000530 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alejandro Perez |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1851577506 PECOS PAC ID: 8527111053 Enrollment ID: I20130805000991 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Regan M Duffy |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1487876827 PECOS PAC ID: 4082869656 Enrollment ID: I20130806000605 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rhonda A Brown |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1083935787 PECOS PAC ID: 5294977922 Enrollment ID: I20130809000086 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia A Gingalewski |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1043300502 PECOS PAC ID: 0042245292 Enrollment ID: I20130816000384 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rui Li |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1689871535 PECOS PAC ID: 3072756170 Enrollment ID: I20130821000058 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cristian Nicu Ghetie |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1104000496 PECOS PAC ID: 4284775727 Enrollment ID: I20130906000259 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jill K Christensen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790004497 PECOS PAC ID: 6204076920 Enrollment ID: I20130906000355 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Greta K Larson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619204583 PECOS PAC ID: 6608918255 Enrollment ID: I20130909000232 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John M Ellison |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245672286 PECOS PAC ID: 2163666306 Enrollment ID: I20130910000411 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Volodymyr Y Dovhyy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003049818 PECOS PAC ID: 8426297268 Enrollment ID: I20130912000385 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Danylle O Kappler |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1881984995 PECOS PAC ID: 4183868128 Enrollment ID: I20130913000241 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Breanne D Brown |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376779041 PECOS PAC ID: 8729232004 Enrollment ID: I20130920000430 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole L Bridges |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609208891 PECOS PAC ID: 9436393949 Enrollment ID: I20130924000549 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica N James |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326471616 PECOS PAC ID: 0143464503 Enrollment ID: I20130925000332 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andreana M Gentile |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134428378 PECOS PAC ID: 3870737240 Enrollment ID: I20130925000488 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kindra Scanlon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154619260 PECOS PAC ID: 7719121193 Enrollment ID: I20130925000585 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evan Alex Hiles |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1356773949 PECOS PAC ID: 0648414938 Enrollment ID: I20130927000073 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cynthia M Easley |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1295074938 PECOS PAC ID: 4385878677 Enrollment ID: I20130927000198 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeremy P Bauer |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1609888742 PECOS PAC ID: 3870727712 Enrollment ID: I20131009000945 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas C Rittman |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1235392473 PECOS PAC ID: 9537315437 Enrollment ID: I20131022001749 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth S Ballner |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1114193430 PECOS PAC ID: 9335310523 Enrollment ID: I20131023001357 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jordan I Roth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649596875 PECOS PAC ID: 4688829401 Enrollment ID: I20131023002024 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erika M Barber |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1881861748 PECOS PAC ID: 9335374529 Enrollment ID: I20131023002110 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa J Sabally |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1992093819 PECOS PAC ID: 6305091992 Enrollment ID: I20131028000351 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ingrid A Cherrytree |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1538327838 PECOS PAC ID: 8022267996 Enrollment ID: I20131029000413 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Salona Shrestha |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003002379 PECOS PAC ID: 5496842486 Enrollment ID: I20131101000541 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ellen M Raney |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1407946577 PECOS PAC ID: 2466687082 Enrollment ID: I20131106001149 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathy K Bak |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861412884 PECOS PAC ID: 9335177476 Enrollment ID: I20131114000034 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeri Turgesen |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1447688916 PECOS PAC ID: 4587890157 Enrollment ID: I20131204001229 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robin K Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124370200 PECOS PAC ID: 4486805504 Enrollment ID: I20131211001522 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Martha P Geisheker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194800961 PECOS PAC ID: 9931271038 Enrollment ID: I20131211002091 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alice S Weston |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902190820 PECOS PAC ID: 7012158330 Enrollment ID: I20131218001844 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carol L Opheikens |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053732677 PECOS PAC ID: 3274762331 Enrollment ID: I20140212001465 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maryann W Ogden |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1811131261 PECOS PAC ID: 9436300845 Enrollment ID: I20140311001902 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew M Evans |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1164647061 PECOS PAC ID: 7113191776 Enrollment ID: I20140312001360 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel H Norfleet |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871889741 PECOS PAC ID: 8224278932 Enrollment ID: I20140321001238 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shai D Rosenfeld |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386904837 PECOS PAC ID: 9931340213 Enrollment ID: I20140326001093 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly S Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578870069 PECOS PAC ID: 3476781055 Enrollment ID: I20140417002086 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joanna K Sullivan |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1275849994 PECOS PAC ID: 5193957488 Enrollment ID: I20140421001801 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yen P Vo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770874430 PECOS PAC ID: 8022241751 Enrollment ID: I20140505001820 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine C Hammond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558613414 PECOS PAC ID: 5193958726 Enrollment ID: I20140505002292 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caitlin M Rice |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1497184824 PECOS PAC ID: 7012140551 Enrollment ID: I20140507001300 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amber L Watters |
|---|---|
| Provider Type | Practitioner - Orofacial Pain |
| Provider Identifiers | NPI Number: 1477786499 PECOS PAC ID: 8022280676 Enrollment ID: I20140514001294 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robbie Bahl |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1942469762 PECOS PAC ID: 8628215365 Enrollment ID: I20140515001627 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Viki Moravec |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831237064 PECOS PAC ID: 9830312073 Enrollment ID: I20140515002077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Derek William Clark |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1518283589 PECOS PAC ID: 1153576962 Enrollment ID: I20140519001422 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian D Becker Broncheau |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1821226713 PECOS PAC ID: 2062687429 Enrollment ID: I20140606001957 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ho-yann Jong |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1699096610 PECOS PAC ID: 9638340730 Enrollment ID: I20140611001576 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Allen Cheng |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1043537707 PECOS PAC ID: 7719101336 Enrollment ID: I20140620000927 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tobias Pusch |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1811189632 PECOS PAC ID: 6901984806 Enrollment ID: I20140707001422 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sorin Cadar |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376854158 PECOS PAC ID: 7911122981 Enrollment ID: I20140707001507 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bethany M Mcclenathan |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1073759841 PECOS PAC ID: 7618109364 Enrollment ID: I20140708001705 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Prakash Ambady |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1962784298 PECOS PAC ID: 0941425771 Enrollment ID: I20140710000902 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tian Yu Davis |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1285970343 PECOS PAC ID: 4284859935 Enrollment ID: I20140714000547 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jay A Shah |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215162318 PECOS PAC ID: 9032395173 Enrollment ID: I20140719000042 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Qian Leng |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154637015 PECOS PAC ID: 1658524723 Enrollment ID: I20140724000599 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel Alexander Ananyev |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255678439 PECOS PAC ID: 1052537255 Enrollment ID: I20140724000913 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sandra A Antonovic |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1184773319 PECOS PAC ID: 9032335922 Enrollment ID: I20140730000710 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael D Goodwin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1568756591 PECOS PAC ID: 5698915312 Enrollment ID: I20140731000593 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura L Gaff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033401906 PECOS PAC ID: 3678790185 Enrollment ID: I20140806002737 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Armasabille Ermita |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629365382 PECOS PAC ID: 1254575145 Enrollment ID: I20140818000399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William T Smith |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1407146822 PECOS PAC ID: 3577717859 Enrollment ID: I20140825001445 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lilith M Judd |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1508032327 PECOS PAC ID: 8921263419 Enrollment ID: I20140826000192 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda J Pickert |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1922232255 PECOS PAC ID: 4486779709 Enrollment ID: I20140911000023 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anne-marie B Mccoy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720085475 PECOS PAC ID: 2567465495 Enrollment ID: I20140918001424 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Crystal L Griffy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902229958 PECOS PAC ID: 6103045158 Enrollment ID: I20140924000767 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua A Raj |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356635395 PECOS PAC ID: 6103066832 Enrollment ID: I20141001000657 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joana Silva |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538583471 PECOS PAC ID: 8527288109 Enrollment ID: I20141002000549 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hien M Bowden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164706313 PECOS PAC ID: 6406087584 Enrollment ID: I20141008002399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesse M Powell |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467710095 PECOS PAC ID: 2769622497 Enrollment ID: I20141009002238 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan L Mudrick |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528250131 PECOS PAC ID: 1658459383 Enrollment ID: I20141016002424 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shiliang Chang |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1710140215 PECOS PAC ID: 3577735034 Enrollment ID: I20141021003146 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Renee Carisio Farber |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1700855517 PECOS PAC ID: 2264525666 Enrollment ID: I20141105001124 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julie M Peterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801202528 PECOS PAC ID: 0749402642 Enrollment ID: I20141110000202 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ian L Liao |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154586105 PECOS PAC ID: 3476728411 Enrollment ID: I20141118002371 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heidi U Ferguson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306810858 PECOS PAC ID: 9638317662 Enrollment ID: I20141120001406 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathaniel K Mccoy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689973182 PECOS PAC ID: 6204068380 Enrollment ID: I20141217000709 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patricia Millan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285854844 PECOS PAC ID: 7315092574 Enrollment ID: I20150102001645 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth Uno |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1962796508 PECOS PAC ID: 0143454744 Enrollment ID: I20150105000916 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbara Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003223264 PECOS PAC ID: 7315261864 Enrollment ID: I20150112000328 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer H Lincoln |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1528275815 PECOS PAC ID: 3173794369 Enrollment ID: I20150119000000 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ramandeep Sidhu |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1295912814 PECOS PAC ID: 7315074465 Enrollment ID: I20150120002027 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward Bieniek |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1083682744 PECOS PAC ID: 8022202647 Enrollment ID: I20150123000096 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jacqueline Sammons |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235539594 PECOS PAC ID: 1052636628 Enrollment ID: I20150203001035 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer A Felker-norling |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1437286986 PECOS PAC ID: 3577888007 Enrollment ID: I20150204001399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Jepson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871927301 PECOS PAC ID: 7810126679 Enrollment ID: I20150204002240 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Trevor Moerkerke |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437449287 PECOS PAC ID: 5193955490 Enrollment ID: I20150225001992 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pia Klamper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467708800 PECOS PAC ID: 6901053800 Enrollment ID: I20150226001647 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eric D Falquist |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841681491 PECOS PAC ID: 1951629120 Enrollment ID: I20150420001123 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brant Ullery |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1588826804 PECOS PAC ID: 4981922903 Enrollment ID: I20150422002206 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cheri L Belling |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023359213 PECOS PAC ID: 5890935761 Enrollment ID: I20150504001273 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John C. Conroy |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1962792713 PECOS PAC ID: 1557515830 Enrollment ID: I20150521000733 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel J Bennett |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740516434 PECOS PAC ID: 8224263140 Enrollment ID: I20150521002590 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia M Curren |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1336403468 PECOS PAC ID: 8426201179 Enrollment ID: I20150528000010 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie L Gorretta |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962898809 PECOS PAC ID: 9436460649 Enrollment ID: I20150615001432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashish A Patel |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1043415870 PECOS PAC ID: 4880905702 Enrollment ID: I20150618002993 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ben Lawrence Pederson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1073856142 PECOS PAC ID: 8022259613 Enrollment ID: I20150623002865 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen Michael Salerno |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851381743 PECOS PAC ID: 4688861529 Enrollment ID: I20150707003239 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Farzaneh Khezri |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1740578582 PECOS PAC ID: 9436461969 Enrollment ID: I20150710002504 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David B Page |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1922241140 PECOS PAC ID: 0648583807 Enrollment ID: I20150716001603 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristen P. Massimino |
|---|---|
| Provider Type | Practitioner - Surgical Oncology |
| Provider Identifiers | NPI Number: 1720208556 PECOS PAC ID: 3375788276 Enrollment ID: I20150727001389 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer Huang |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1023214533 PECOS PAC ID: 9931343019 Enrollment ID: I20150728004368 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Phillip Letourneau |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1891021960 PECOS PAC ID: 1658409040 Enrollment ID: I20150728006118 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Finigan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1043444078 PECOS PAC ID: 2668636994 Enrollment ID: I20150803003054 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aaron B Lyles |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1679866271 PECOS PAC ID: 7517271521 Enrollment ID: I20150805006376 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alireza Shabani Ardali |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1083862403 PECOS PAC ID: 4789730508 Enrollment ID: I20150811006094 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Augustine Okechukwu Okeke |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1043572696 PECOS PAC ID: 2567697998 Enrollment ID: I20150818004707 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie L Randles |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619103389 PECOS PAC ID: 1850549528 Enrollment ID: I20150819007378 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Palaniappan Chidambaram |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1770651200 PECOS PAC ID: 8729024146 Enrollment ID: I20150821013220 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gina L Westhoff |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1598927261 PECOS PAC ID: 8820240567 Enrollment ID: I20150825004570 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caroline B Mcculley |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1558709089 PECOS PAC ID: 7810122249 Enrollment ID: I20150829000120 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lela T Gonzales |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1720348568 PECOS PAC ID: 7012158439 Enrollment ID: I20150831000750 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charles A Saltalamacchia |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336431881 PECOS PAC ID: 4688811219 Enrollment ID: I20150831003143 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elise J Mahoney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790054831 PECOS PAC ID: 9032379193 Enrollment ID: I20150903002483 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jose M Negron |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548351877 PECOS PAC ID: 7719985209 Enrollment ID: I20150904000870 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Terena D Gimmillaro |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235574955 PECOS PAC ID: 5395970214 Enrollment ID: I20150908001807 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather E Merry |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1538278700 PECOS PAC ID: 5395915284 Enrollment ID: I20150909003390 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chelsea Anne Draper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912257015 PECOS PAC ID: 4789991530 Enrollment ID: I20150911000619 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Allison C Huang |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1598028854 PECOS PAC ID: 4082921770 Enrollment ID: I20150911002504 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thuy-tien V Pham |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1841551041 PECOS PAC ID: 3173764453 Enrollment ID: I20150917001546 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Polly C Molden |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1023430238 PECOS PAC ID: 2365759693 Enrollment ID: I20150917002775 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mischa Ronick |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780977371 PECOS PAC ID: 6204144132 Enrollment ID: I20150925002584 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evan J Fertig |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1275515918 PECOS PAC ID: 1557390218 Enrollment ID: I20150928001969 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Biggya L Sapkota |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1306006135 PECOS PAC ID: 0244405272 Enrollment ID: I20151007003377 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaclyn Jones |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255614624 PECOS PAC ID: 7810121258 Enrollment ID: I20151008002971 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca L Jorgensen |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932579760 PECOS PAC ID: 3870802689 Enrollment ID: I20151019000917 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Frances A Derook |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1922098060 PECOS PAC ID: 2668453929 Enrollment ID: I20151023001133 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Monica H Demasi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871525303 PECOS PAC ID: 2668477977 Enrollment ID: I20151026000965 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Siddharth K Joshi |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1467710632 PECOS PAC ID: 9335458736 Enrollment ID: I20151026002849 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie N Wong |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851760904 PECOS PAC ID: 0042520355 Enrollment ID: I20151116002408 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marcie K Drury Brown |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1609822139 PECOS PAC ID: 1850468679 Enrollment ID: I20151117002500 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alea Rae Garces |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629440656 PECOS PAC ID: 4688974900 Enrollment ID: I20151118001278 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Herbert A Krob |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1780615625 PECOS PAC ID: 0941303804 Enrollment ID: I20151119000427 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel A Kvamme |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1003080284 PECOS PAC ID: 3779883285 Enrollment ID: I20151204000682 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elisa A Rudd |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1821413444 PECOS PAC ID: 2466753777 Enrollment ID: I20151210000949 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erandi Liyanaarachchi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518227651 PECOS PAC ID: 8820399736 Enrollment ID: I20151218001105 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mini Zhang |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1316238603 PECOS PAC ID: 8729231881 Enrollment ID: I20151221000023 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shushaun B Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891101671 PECOS PAC ID: 6608096433 Enrollment ID: I20151229001532 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Denise M Viss |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477927606 PECOS PAC ID: 8729380290 Enrollment ID: I20151230002036 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexander M Morss |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1225096167 PECOS PAC ID: 0648240226 Enrollment ID: I20160118000506 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rayoung Chung |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588002976 PECOS PAC ID: 8921249178 Enrollment ID: I20160129000428 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura Andreas |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1952766792 PECOS PAC ID: 7214231935 Enrollment ID: I20160201001221 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ellen Petersen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508235326 PECOS PAC ID: 2163726787 Enrollment ID: I20160202001547 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laurel B Tor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649636648 PECOS PAC ID: 7911201363 Enrollment ID: I20160205001166 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brandy Hayes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285091892 PECOS PAC ID: 5991002990 Enrollment ID: I20160317001967 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Molly F Weeber |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1396009254 PECOS PAC ID: 0547567612 Enrollment ID: I20160405001206 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarita K Sapkota |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255611760 PECOS PAC ID: 0244554707 Enrollment ID: I20160415001992 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony D Gaston |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588979553 PECOS PAC ID: 9436378882 Enrollment ID: I20160419001372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelly Erin Myers Sugahara |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740586601 PECOS PAC ID: 4082887351 Enrollment ID: I20160421000651 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Graham A Phelps |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114358033 PECOS PAC ID: 1850520503 Enrollment ID: I20160426002128 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gita D Gelfer |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1023455805 PECOS PAC ID: 8123253531 Enrollment ID: I20160517000469 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather A Wilson |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1962649848 PECOS PAC ID: 2365732831 Enrollment ID: I20160613001255 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Annalisa C Hawthorne |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922445394 PECOS PAC ID: 3476784356 Enrollment ID: I20160701001773 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aaron W Spaugy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1356608335 PECOS PAC ID: 4385881424 Enrollment ID: I20160705000450 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anna M Meyers |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1184986325 PECOS PAC ID: 3779875133 Enrollment ID: I20160706001286 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa A Wollan Francis |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1124280367 PECOS PAC ID: 0042452997 Enrollment ID: I20160706002728 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristi L Keats |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336541846 PECOS PAC ID: 8325260177 Enrollment ID: I20160706002764 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Miranda S Boeh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649574443 PECOS PAC ID: 0244522258 Enrollment ID: I20160712002752 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Diane Halvarson West |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1336583103 PECOS PAC ID: 4688808181 Enrollment ID: I20160721000689 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason John Heino |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457799017 PECOS PAC ID: 3971738790 Enrollment ID: I20160725001856 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Justin E Osborn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649355462 PECOS PAC ID: 9638156144 Enrollment ID: I20160727001683 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas P Huber |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1740205830 PECOS PAC ID: 5496885881 Enrollment ID: I20160801002764 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary E Kuebrich |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477902617 PECOS PAC ID: 5890089635 Enrollment ID: I20160802002300 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katie M Riskey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1962615658 PECOS PAC ID: 3476847138 Enrollment ID: I20160803002821 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bryan Madden |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1164715991 PECOS PAC ID: 7214169986 Enrollment ID: I20160809002300 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tira E Nesset |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245617158 PECOS PAC ID: 4981998994 Enrollment ID: I20160812001268 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William W Cuff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679913735 PECOS PAC ID: 4880914472 Enrollment ID: I20160812002168 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Clarice C Calopiz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316051410 PECOS PAC ID: 6800828518 Enrollment ID: I20160815000666 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lan-anh Nguyen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356414536 PECOS PAC ID: 8426020926 Enrollment ID: I20160815001032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew C Becker |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679817704 PECOS PAC ID: 6204070352 Enrollment ID: I20160815001989 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Karina M Squire |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154772911 PECOS PAC ID: 2769776632 Enrollment ID: I20160816001213 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah M Hopkins |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1871892653 PECOS PAC ID: 5698994887 Enrollment ID: I20160819000923 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel M Etringer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124456470 PECOS PAC ID: 7113154576 Enrollment ID: I20160822002369 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lara A Weyl |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1629333414 PECOS PAC ID: 6204121726 Enrollment ID: I20160823002499 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dale E Milam |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427428804 PECOS PAC ID: 8628363082 Enrollment ID: I20160824000790 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia C Swanson-birchill |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1023140597 PECOS PAC ID: 7810134897 Enrollment ID: I20160831001034 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel M Rackow |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1285862565 PECOS PAC ID: 0547499238 Enrollment ID: I20160901000763 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah W Milam |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699145078 PECOS PAC ID: 1850687682 Enrollment ID: I20160902002013 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin M Ware |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922411404 PECOS PAC ID: 8022233196 Enrollment ID: I20160906002699 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel F O'neill |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1588007926 PECOS PAC ID: 4183944598 Enrollment ID: I20160913000785 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas Ponzetti |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669925582 PECOS PAC ID: 7517253826 Enrollment ID: I20160913002416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather M Kong |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1891013603 PECOS PAC ID: 4183939887 Enrollment ID: I20160920002681 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paula J Prince |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114165503 PECOS PAC ID: 9931496742 Enrollment ID: I20160922000425 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Juliette Eve Moore |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1700144615 PECOS PAC ID: 6901125939 Enrollment ID: I20160923002191 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan Locher |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1003133620 PECOS PAC ID: 0446547012 Enrollment ID: I20160926000583 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer L Yeast |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285996926 PECOS PAC ID: 2062733900 Enrollment ID: I20160926002411 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rhett J Butler |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1275979171 PECOS PAC ID: 7719112630 Enrollment ID: I20160927002379 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel Fremont Goodwin |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1407972821 PECOS PAC ID: 4587769294 Enrollment ID: I20160928002127 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shannon R Ehleringer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1568606770 PECOS PAC ID: 9830368125 Enrollment ID: I20161004002075 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Deborah K Fulkerson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770791527 PECOS PAC ID: 4981992153 Enrollment ID: I20161004002689 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah R Sellevaag |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1811345598 PECOS PAC ID: 0547558421 Enrollment ID: I20161007001718 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeannie Y Chun |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1639128499 PECOS PAC ID: 5092986885 Enrollment ID: I20161012002141 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexandra Gabrielle Bond |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1427497031 PECOS PAC ID: 1658693304 Enrollment ID: I20161020001329 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Suzanne K Wallace |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1467587618 PECOS PAC ID: 7012295363 Enrollment ID: I20161020002394 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James Andrew Smith |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1659439214 PECOS PAC ID: 7517151764 Enrollment ID: I20161025001214 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Beth Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285832360 PECOS PAC ID: 6305023375 Enrollment ID: I20161026002118 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Celina C Sears |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790989598 PECOS PAC ID: 7214215144 Enrollment ID: I20161028000126 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Krister P Freese |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1104053388 PECOS PAC ID: 9537488804 Enrollment ID: I20161104000830 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tanya Rogers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851750285 PECOS PAC ID: 7911286372 Enrollment ID: I20161108001579 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elisabeth Anacius |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003109828 PECOS PAC ID: 7810155090 Enrollment ID: I20161109001708 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Whitney A Serafini |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770033474 PECOS PAC ID: 2567741754 Enrollment ID: I20161110001448 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lee M Anthony |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1336551555 PECOS PAC ID: 2769609551 Enrollment ID: I20161115001103 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pawani Sachar |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1689955536 PECOS PAC ID: 9234421413 Enrollment ID: I20161121000373 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy Dodson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588844112 PECOS PAC ID: 6103105762 Enrollment ID: I20161122002104 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew R Riley |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1164486759 PECOS PAC ID: 7810277266 Enrollment ID: I20161201000963 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Angela Elaine S Lennon |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1245430933 PECOS PAC ID: 2860516218 Enrollment ID: I20161201001142 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michelle C Welborn |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1821257718 PECOS PAC ID: 4082838321 Enrollment ID: I20161205001058 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura A Mcguire |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1841386703 PECOS PAC ID: 1153412515 Enrollment ID: I20161230001308 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shaun M Burns |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1487810271 PECOS PAC ID: 0941581003 Enrollment ID: I20170103001476 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jane H Bryant |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700928728 PECOS PAC ID: 4284929688 Enrollment ID: I20170109002634 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erika Helen Wilson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1184967986 PECOS PAC ID: 4789824970 Enrollment ID: I20170124002465 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Enrique Barrera |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528337201 PECOS PAC ID: 2769764786 Enrollment ID: I20170126000644 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine Erickson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619125689 PECOS PAC ID: 4789577503 Enrollment ID: I20170202000570 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marcia Woodburn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417343229 PECOS PAC ID: 2062795180 Enrollment ID: I20170214002851 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaime Biava |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538545082 PECOS PAC ID: 3971887753 Enrollment ID: I20170222000934 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelli R Harrington-bollenbaugh |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1992107544 PECOS PAC ID: 6608150289 Enrollment ID: I20170227001040 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Asher Pema Ngodrub Caldwell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699915355 PECOS PAC ID: 0244372837 Enrollment ID: I20170313001701 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Charles Burke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952851685 PECOS PAC ID: 2466737069 Enrollment ID: I20170322001458 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gina C Easley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427357680 PECOS PAC ID: 2466738810 Enrollment ID: I20170419000973 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy T Hartman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588105191 PECOS PAC ID: 8426334731 Enrollment ID: I20170420000980 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbara J Torres |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1871599217 PECOS PAC ID: 7214911148 Enrollment ID: I20170425000925 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Meghan Elizabeth Wallace |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194171579 PECOS PAC ID: 2466739420 Enrollment ID: I20170501002104 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsey R Mckinley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1265845754 PECOS PAC ID: 8022233279 Enrollment ID: I20170502002710 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sasha M Preston |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760849780 PECOS PAC ID: 5092092619 Enrollment ID: I20170509002767 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert K Hudon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700299294 PECOS PAC ID: 2365667516 Enrollment ID: I20170522002093 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian Bao |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1952729519 PECOS PAC ID: 2668698457 Enrollment ID: I20170602001448 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Victoria Reichman |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659785590 PECOS PAC ID: 8224306188 Enrollment ID: I20170616001962 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel E Westerdahl |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1396061834 PECOS PAC ID: 9830319961 Enrollment ID: I20170621000925 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vincent Joseph Santo |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1841424108 PECOS PAC ID: 8729223425 Enrollment ID: I20170621002043 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Karen H Nagao |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396032488 PECOS PAC ID: 6901174697 Enrollment ID: I20170621002736 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ravikiran Ellandula |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1356623177 PECOS PAC ID: 7517183304 Enrollment ID: I20170621003015 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie A Williams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851845440 PECOS PAC ID: 9537437082 Enrollment ID: I20170626000324 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathleen D Dronkowski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154602902 PECOS PAC ID: 4789952250 Enrollment ID: I20170626001002 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Son T Do |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1285668822 PECOS PAC ID: 2668371337 Enrollment ID: I20170626001871 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William D Ruegg |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780900969 PECOS PAC ID: 7911140017 Enrollment ID: I20170628003061 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nandish P Dayal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235665522 PECOS PAC ID: 2567731862 Enrollment ID: I20170629001700 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sohil R Makwana |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1487949582 PECOS PAC ID: 8820304389 Enrollment ID: I20170707002856 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel M Fischer |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1275875189 PECOS PAC ID: 4688978307 Enrollment ID: I20170711003301 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ryan P Jacobson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831300672 PECOS PAC ID: 4284903980 Enrollment ID: I20170712002564 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carl B Anderson |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1871619080 PECOS PAC ID: 3173686110 Enrollment ID: I20170713002016 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jodi R Moon |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1679891501 PECOS PAC ID: 3971873589 Enrollment ID: I20170713003674 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zachary G Pena |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1538592399 PECOS PAC ID: 2264652593 Enrollment ID: I20170714001374 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher Schraner |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1578959466 PECOS PAC ID: 0446520027 Enrollment ID: I20170714002820 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brandon M Jones |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1043447873 PECOS PAC ID: 8426210675 Enrollment ID: I20170718001370 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaleh M Rahimi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235542622 PECOS PAC ID: 6406175462 Enrollment ID: I20170719003698 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robin N Jackson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1700083185 PECOS PAC ID: 6901176924 Enrollment ID: I20170725002077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Suzanne L Mckenzie |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1063967628 PECOS PAC ID: 4082984901 Enrollment ID: I20170725002157 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christina A Heiberg |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1336676691 PECOS PAC ID: 4385914274 Enrollment ID: I20170726000968 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa L Weismiller |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1639290521 PECOS PAC ID: 5193095917 Enrollment ID: I20170726002926 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie M Griffith |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1497167613 PECOS PAC ID: 8325265317 Enrollment ID: I20170726004011 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Divya U Soman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1750547535 PECOS PAC ID: 7315115128 Enrollment ID: I20170801003811 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bryan D Thieme |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1639333511 PECOS PAC ID: 2769753227 Enrollment ID: I20170802002620 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sareena D Oncea |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1609207406 PECOS PAC ID: 6608179353 Enrollment ID: I20170804001990 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel Nmi Davila Bradley |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1245587823 PECOS PAC ID: 7416174602 Enrollment ID: I20170804002976 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey J Buenjemia |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1982896932 PECOS PAC ID: 2961590245 Enrollment ID: I20170808003995 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Herbert H Lim |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235124520 PECOS PAC ID: 9931135324 Enrollment ID: I20170811002431 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christina E Fratangelo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154680817 PECOS PAC ID: 5890943609 Enrollment ID: I20170815001385 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicoleta C Voian |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1417191081 PECOS PAC ID: 3779742184 Enrollment ID: I20170815002581 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ricky Chen |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1063779213 PECOS PAC ID: 6901039734 Enrollment ID: I20170816004306 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher J Kim |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720498512 PECOS PAC ID: 5698995306 Enrollment ID: I20170821002908 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Glen C Ritchie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477958569 PECOS PAC ID: 4284959289 Enrollment ID: I20170824001018 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ivan I Biley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1073993069 PECOS PAC ID: 7618280611 Enrollment ID: I20170828003403 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alison L Christy |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1639436074 PECOS PAC ID: 8921243791 Enrollment ID: I20170830003060 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lena K Hillenburg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1710042502 PECOS PAC ID: 9335117795 Enrollment ID: I20170905000113 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Siobhan J Conley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407811433 PECOS PAC ID: 7113938473 Enrollment ID: I20170906003517 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Austen Brown |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1689094583 PECOS PAC ID: 6901024595 Enrollment ID: I20170915001184 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel J Bouton |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1386934388 PECOS PAC ID: 0143469270 Enrollment ID: I20170925001705 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tyler S Mittelstaedt |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1053678284 PECOS PAC ID: 4486809076 Enrollment ID: I20170926004089 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward Y Lin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659783546 PECOS PAC ID: 0446525174 Enrollment ID: I20171006000029 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jamie M Libera |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1710424122 PECOS PAC ID: 7911272505 Enrollment ID: I20171006003103 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Reza Kafi |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1891737201 PECOS PAC ID: 6204851793 Enrollment ID: I20171017000591 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katrin Beene |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1518476282 PECOS PAC ID: 9537435623 Enrollment ID: I20171017002050 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathryn O Fuchs |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1962796946 PECOS PAC ID: 2567768625 Enrollment ID: I20171023002432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susan K Glinka |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1326588708 PECOS PAC ID: 2264708007 Enrollment ID: I20171024001615 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nancy A Chang |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1710241559 PECOS PAC ID: 5799927802 Enrollment ID: I20171108003004 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Beverly D Hansen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740479831 PECOS PAC ID: 2860758364 Enrollment ID: I20171116002117 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelley Crusius |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801145867 PECOS PAC ID: 6002173366 Enrollment ID: I20171122001349 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mohamed Refaat |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1053607457 PECOS PAC ID: 1557591625 Enrollment ID: I20171129000688 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Grace Fitch |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1699959429 PECOS PAC ID: 9739446758 Enrollment ID: I20171129003558 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathleen Loretta Strooband |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1902319908 PECOS PAC ID: 7810254851 Enrollment ID: I20171130000753 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Callie Sockler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548716764 PECOS PAC ID: 1153689484 Enrollment ID: I20171214002261 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathan Way |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104251263 PECOS PAC ID: 5597023192 Enrollment ID: I20180102001725 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nina R Frank |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1215215736 PECOS PAC ID: 5092031294 Enrollment ID: I20180105001326 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Soohyun Karen Yoon |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1104026285 PECOS PAC ID: 6002000247 Enrollment ID: I20180110002703 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica L Newgard |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1164895173 PECOS PAC ID: 4789943119 Enrollment ID: I20180110003315 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aravind Chandra |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255742466 PECOS PAC ID: 3375809080 Enrollment ID: I20180118001601 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristine J Dukart-harrington |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477914067 PECOS PAC ID: 2769774744 Enrollment ID: I20180119001572 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christiann Michelle Collins |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1205029345 PECOS PAC ID: 3274628466 Enrollment ID: I20180122002385 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gabriel Larson |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1801162789 PECOS PAC ID: 4284875410 Enrollment ID: I20180123000372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anna L Hemphill |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942591813 PECOS PAC ID: 0840426367 Enrollment ID: I20180124001474 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura Michelle Donart |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1336653518 PECOS PAC ID: 6507126133 Enrollment ID: I20180130002786 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine Seunga Chun |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376050989 PECOS PAC ID: 6204196793 Enrollment ID: I20180131003114 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Oliver Loriega Arquero |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962713776 PECOS PAC ID: 3173763141 Enrollment ID: I20180213001046 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer Shannon Haag |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285095398 PECOS PAC ID: 9133411671 Enrollment ID: I20180214001079 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tessa B Collins |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1821009556 PECOS PAC ID: 7113972860 Enrollment ID: I20180222002150 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Torin Patrick Fitton |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1821148644 PECOS PAC ID: 8022008465 Enrollment ID: I20180306001034 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin J Hartwig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578008397 PECOS PAC ID: 2860754009 Enrollment ID: I20180327002925 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael Long Trieu |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1538280508 PECOS PAC ID: 3072730597 Enrollment ID: I20180404001358 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Clarke Young |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1962906958 PECOS PAC ID: 8820351422 Enrollment ID: I20180412002152 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen Teng-yip Yau |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1154616035 PECOS PAC ID: 6800193012 Enrollment ID: I20180418000975 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole Marie Rudy |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1023510161 PECOS PAC ID: 8628333630 Enrollment ID: I20180522002117 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas Thompson Olney |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1447519830 PECOS PAC ID: 4183936735 Enrollment ID: I20180529003063 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hoda A Ilias |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1114315603 PECOS PAC ID: 1850656513 Enrollment ID: I20180530000402 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin Pedroja |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1821477910 PECOS PAC ID: 5496069833 Enrollment ID: I20180531001899 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica Ellen Rice |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1457778656 PECOS PAC ID: 2062639818 Enrollment ID: I20180619001833 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elena Styles |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912394743 PECOS PAC ID: 2062773369 Enrollment ID: I20180625000721 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Duy Quang Tran |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134115512 PECOS PAC ID: 3678587425 Enrollment ID: I20180625000788 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caitlin D Duran |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679063531 PECOS PAC ID: 5193071496 Enrollment ID: I20180628001563 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John Noel Dussel |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1902192396 PECOS PAC ID: 5496049504 Enrollment ID: I20180628002241 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jacob P Casey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942689930 PECOS PAC ID: 9032421763 Enrollment ID: I20180705001919 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michele Lynn Babicky |
|---|---|
| Provider Type | Practitioner - Surgical Oncology |
| Provider Identifiers | NPI Number: 1871742478 PECOS PAC ID: 6406103175 Enrollment ID: I20180726001003 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cassandra Michelle Niemi |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1861781767 PECOS PAC ID: 3476708470 Enrollment ID: I20180807003952 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joseph R Smith |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1003983818 PECOS PAC ID: 0143255489 Enrollment ID: I20180809000639 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Randolph K Cribbs |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1770675563 PECOS PAC ID: 3274614169 Enrollment ID: I20180809005374 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Allison Claire Nauta |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1922255322 PECOS PAC ID: 0840437992 Enrollment ID: I20180815003608 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stacy Michelle Butler |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1659799385 PECOS PAC ID: 7113223074 Enrollment ID: I20180827003281 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Margaret J Black |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659699528 PECOS PAC ID: 0648584193 Enrollment ID: I20180828000858 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mark Wilkison |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1912394016 PECOS PAC ID: 6800104241 Enrollment ID: I20180829002754 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tyler Cole Duffield |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1962842203 PECOS PAC ID: 9537419098 Enrollment ID: I20180904000692 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Phebe L Matsen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1760822290 PECOS PAC ID: 3274848932 Enrollment ID: I20180904001571 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brittany N Arnold |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1851731673 PECOS PAC ID: 6406163690 Enrollment ID: I20180906003468 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andreas M Schneider |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1609036136 PECOS PAC ID: 0143441683 Enrollment ID: I20180910002378 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kyle David Walker |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689068033 PECOS PAC ID: 1951600022 Enrollment ID: I20180911001586 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Roma Moza |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063779569 PECOS PAC ID: 5991090938 Enrollment ID: I20180914001032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jahnavi Chandrashekar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427442664 PECOS PAC ID: 0345557831 Enrollment ID: I20180914002644 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eric T Burgh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1144679895 PECOS PAC ID: 9931491412 Enrollment ID: I20180918003230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sandra Iloka |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114311222 PECOS PAC ID: 3971812108 Enrollment ID: I20180920001959 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas L Stucky |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1912265190 PECOS PAC ID: 6204072671 Enrollment ID: I20180921002075 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer Rose Parr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538656434 PECOS PAC ID: 5799036273 Enrollment ID: I20180921002091 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amelia H Baker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144649179 PECOS PAC ID: 4082831763 Enrollment ID: I20181008003105 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Randolph Smith |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1487176657 PECOS PAC ID: 7517220668 Enrollment ID: I20181010000855 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaecelle Guadiz Galeniece |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013321389 PECOS PAC ID: 2860763273 Enrollment ID: I20181021000011 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura E Holton |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1487090270 PECOS PAC ID: 5890920714 Enrollment ID: I20181022002396 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lan Ban |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134500358 PECOS PAC ID: 6608189816 Enrollment ID: I20181025001927 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pavel Mitaru |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1760862494 PECOS PAC ID: 1557673597 Enrollment ID: I20181025003118 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsay Megan Sparks |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336405042 PECOS PAC ID: 7618111204 Enrollment ID: I20181026000541 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer M Goodrich |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174002976 PECOS PAC ID: 8628321346 Enrollment ID: I20181026001448 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shana M Mcclung |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1992084438 PECOS PAC ID: 8123371796 Enrollment ID: I20181029001580 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathryn R Rompala |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730563214 PECOS PAC ID: 0648571992 Enrollment ID: I20181029001842 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa K Sanders |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093128571 PECOS PAC ID: 9537384623 Enrollment ID: I20181105003497 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joseph Daniel Gottfried |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1801829262 PECOS PAC ID: 4486799483 Enrollment ID: I20181112001819 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason Baker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154702538 PECOS PAC ID: 6204140080 Enrollment ID: I20181126003535 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Molly Christine Davis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154809903 PECOS PAC ID: 1658625918 Enrollment ID: I20181126003706 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ted Hideki Yamamoto |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689012015 PECOS PAC ID: 2466737960 Enrollment ID: I20181130000136 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexander H Smith |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1891121802 PECOS PAC ID: 7012251564 Enrollment ID: I20181210003105 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anna L Hiebert |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275008096 PECOS PAC ID: 0648515882 Enrollment ID: I20181217002517 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert V Eller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770556201 PECOS PAC ID: 2264407345 Enrollment ID: I20190102000149 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Muhammad U Farooq |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598945156 PECOS PAC ID: 8729132857 Enrollment ID: I20190108000896 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heather L Jorgensen |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1548787708 PECOS PAC ID: 7517203797 Enrollment ID: I20190109000130 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ayodeji A Oduola |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942530266 PECOS PAC ID: 6305009077 Enrollment ID: I20190110000750 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick James Graham |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437624038 PECOS PAC ID: 6901142090 Enrollment ID: I20190110001210 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alefiyah Rajabali |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1386925899 PECOS PAC ID: 7517127467 Enrollment ID: I20190118001699 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesse Dean Matthews |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851566822 PECOS PAC ID: 6204007040 Enrollment ID: I20190122002682 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eleanor B Debakker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831669191 PECOS PAC ID: 7416294426 Enrollment ID: I20190129003655 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine Michelle Elstun |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114963717 PECOS PAC ID: 5395747943 Enrollment ID: I20190201001374 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael J Dienberg |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1003200122 PECOS PAC ID: 6002122801 Enrollment ID: I20190214002236 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katie B Mcculloch |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1013454842 PECOS PAC ID: 1052698925 Enrollment ID: I20190225000930 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wendi Kay Drummond |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1417160797 PECOS PAC ID: 9739272428 Enrollment ID: I20190225001675 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Alise Popp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851899884 PECOS PAC ID: 2769721026 Enrollment ID: I20190304001660 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gritz Pierre |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1215319140 PECOS PAC ID: 2961718259 Enrollment ID: I20190311000280 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tarra Lynne Castillo |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1235459041 PECOS PAC ID: 1355680216 Enrollment ID: I20190312000448 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maysee Dawn Salleva |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1326336777 PECOS PAC ID: 0345478665 Enrollment ID: I20190313002708 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy Chu Tsai |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1588831713 PECOS PAC ID: 2264604735 Enrollment ID: I20190319000062 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelsey Lander |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700397114 PECOS PAC ID: 5092074310 Enrollment ID: I20190321000438 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Anne Joseph Nidiry |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518041045 PECOS PAC ID: 2264533249 Enrollment ID: I20190329002038 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jonathan Ryan Fordyce |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447736608 PECOS PAC ID: 8628326626 Enrollment ID: I20190401000923 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrea L Purtzer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447702428 PECOS PAC ID: 6204116866 Enrollment ID: I20190401002237 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erin R Molstad |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487134193 PECOS PAC ID: 2264773225 Enrollment ID: I20190401002458 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenna Hannah Gaines |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518419704 PECOS PAC ID: 1456631290 Enrollment ID: I20190402000913 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert M Bernstein |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1619951548 PECOS PAC ID: 0648286609 Enrollment ID: I20190405000171 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kyla J Laraway |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1598202152 PECOS PAC ID: 7012258239 Enrollment ID: I20190416001074 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Virginia Sohn Kelly |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1043324270 PECOS PAC ID: 7315847449 Enrollment ID: I20190416001521 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesse Akaki Hodson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518435585 PECOS PAC ID: 7911248174 Enrollment ID: I20190416002457 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Michelle Mcintyre |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1326526203 PECOS PAC ID: 3072854728 Enrollment ID: I20190417000447 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bruce Geryk |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1275794802 PECOS PAC ID: 5092933846 Enrollment ID: I20190422001901 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Arnold Cha |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811320179 PECOS PAC ID: 0749505998 Enrollment ID: I20190522000408 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Husameddin Rawhi El-bakri |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851660955 PECOS PAC ID: 0547421224 Enrollment ID: I20190529003174 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Catherine Y.h. Wagoner |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1487627550 PECOS PAC ID: 6002080470 Enrollment ID: I20190603002210 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barbara Deborah Mandell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1568925980 PECOS PAC ID: 0446583660 Enrollment ID: I20190603002469 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Devon Charles Baker |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912361833 PECOS PAC ID: 9830455443 Enrollment ID: I20190606002821 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Isaac Kim |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1801243530 PECOS PAC ID: 9335431824 Enrollment ID: I20190607000492 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Imran Mohamedy |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1841226255 PECOS PAC ID: 5395709562 Enrollment ID: I20190607001826 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susan Lien |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558924753 PECOS PAC ID: 7810220712 Enrollment ID: I20190607002101 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew Williams |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1154776359 PECOS PAC ID: 4082961941 Enrollment ID: I20190610001060 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael H Bourne |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1881030443 PECOS PAC ID: 1951549948 Enrollment ID: I20190619003354 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hidekazu Hosono |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1821234170 PECOS PAC ID: 1759552557 Enrollment ID: I20190620002971 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Annie W Chiu |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1376924670 PECOS PAC ID: 4880980192 Enrollment ID: I20190621001380 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah J Wolff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649682576 PECOS PAC ID: 9234410309 Enrollment ID: I20190621002295 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew A Nguyen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851731681 PECOS PAC ID: 7719280684 Enrollment ID: I20190624000917 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin D Houser |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174956049 PECOS PAC ID: 4284927088 Enrollment ID: I20190624000959 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenna Elizabeth Kay |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1760771380 PECOS PAC ID: 0446478531 Enrollment ID: I20190624001090 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aika Shepard Gumboc |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1073599528 PECOS PAC ID: 1456685544 Enrollment ID: I20190624001663 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edyth R Lee Barnes |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760836696 PECOS PAC ID: 8820388119 Enrollment ID: I20190624003279 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lily Davis |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932501186 PECOS PAC ID: 6608100664 Enrollment ID: I20190625001432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Rachel Garey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952798159 PECOS PAC ID: 1153664461 Enrollment ID: I20190625001473 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Derrick Evan Hall |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1497104715 PECOS PAC ID: 4880966696 Enrollment ID: I20190625002160 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rhezarie Mae A Agtarap |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023576659 PECOS PAC ID: 8729312681 Enrollment ID: I20190626001557 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eric P Tubbs |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316107477 PECOS PAC ID: 9931396546 Enrollment ID: I20190627003563 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Traci Ackron |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336588789 PECOS PAC ID: 3375836455 Enrollment ID: I20190701001967 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth S Hutchinson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1205269800 PECOS PAC ID: 3678865474 Enrollment ID: I20190711001665 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa A Olson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679892756 PECOS PAC ID: 7214202324 Enrollment ID: I20190712002545 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine A Mayers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821584889 PECOS PAC ID: 4789919622 Enrollment ID: I20190715001059 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ian D Ledford |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427425818 PECOS PAC ID: 5890089064 Enrollment ID: I20190716001415 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Omar Nabil Horani |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962897264 PECOS PAC ID: 5294038501 Enrollment ID: I20190716002659 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hayden T Oldham |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164817045 PECOS PAC ID: 3870801129 Enrollment ID: I20190716003030 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua J Kim |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1851633077 PECOS PAC ID: 0143556654 Enrollment ID: I20190722001983 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robert Carl Isler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225246523 PECOS PAC ID: 0840526893 Enrollment ID: I20190729002241 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sanjog Bastola |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1922459064 PECOS PAC ID: 4981996253 Enrollment ID: I20190731004037 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael Z Saladik |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1710327473 PECOS PAC ID: 3072806892 Enrollment ID: I20190802000949 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evelyn Mary Brosnan |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1497098941 PECOS PAC ID: 2668771825 Enrollment ID: I20190802001354 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katrine Kwiatkowski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588194179 PECOS PAC ID: 9830426543 Enrollment ID: I20190802002245 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ewen J Harrison |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841647559 PECOS PAC ID: 3779877378 Enrollment ID: I20190805000782 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shahana Falah Baig-lewis |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1982066858 PECOS PAC ID: 9436446143 Enrollment ID: I20190805001394 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lydia A Raney |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114374006 PECOS PAC ID: 4688955701 Enrollment ID: I20190807003971 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christa J Cerra |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801298484 PECOS PAC ID: 0244558047 Enrollment ID: I20190809000312 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin A Babb |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417301151 PECOS PAC ID: 2567755945 Enrollment ID: I20190814001568 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samuel Grovenburg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548624166 PECOS PAC ID: 7416243688 Enrollment ID: I20190814003129 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shejuti Guha |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952751505 PECOS PAC ID: 8628321973 Enrollment ID: I20190820004275 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sriram Ravi |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1831456979 PECOS PAC ID: 4183869555 Enrollment ID: I20190820004298 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaclyn Renee Derosso |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1184186447 PECOS PAC ID: 2668700964 Enrollment ID: I20190823003504 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Wendy W Yu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1184016099 PECOS PAC ID: 5597085399 Enrollment ID: I20190827000686 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary E Walker |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1639730666 PECOS PAC ID: 3274861117 Enrollment ID: I20190829003663 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dana Lynn Moussalli |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073172615 PECOS PAC ID: 2163751793 Enrollment ID: I20190908000010 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel L Zubko |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578737342 PECOS PAC ID: 7012189889 Enrollment ID: I20190909003266 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sonam Ravindra Kiwalkar |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1609215987 PECOS PAC ID: 0042592552 Enrollment ID: I20190910001414 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Barry D Pederson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215208855 PECOS PAC ID: 1254574247 Enrollment ID: I20190910002974 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elise Larson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043673619 PECOS PAC ID: 5193011419 Enrollment ID: I20190911001910 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jocelyn C Smith |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1083018204 PECOS PAC ID: 3678821741 Enrollment ID: I20190911003491 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pratik D Bhattacharya |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1528212768 PECOS PAC ID: 1355529116 Enrollment ID: I20190917002443 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole R Benthin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407400500 PECOS PAC ID: 0941530869 Enrollment ID: I20190919001028 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tracy Bazan |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1487073789 PECOS PAC ID: 0547489841 Enrollment ID: I20190919001910 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alina K Satterfield |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467881441 PECOS PAC ID: 2567743685 Enrollment ID: I20190919002520 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Viva Wheaton |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1528532884 PECOS PAC ID: 5496083305 Enrollment ID: I20190923002909 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amelie M Wegner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285067132 PECOS PAC ID: 3476847849 Enrollment ID: I20190924002255 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth Leah Blackford |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265910590 PECOS PAC ID: 8022348507 Enrollment ID: I20190925003756 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rajpreet Singh |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1316391956 PECOS PAC ID: 8022305473 Enrollment ID: I20191001001964 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer G Rodgers |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1962812891 PECOS PAC ID: 6709007495 Enrollment ID: I20191021002305 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zheru Li |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578718755 PECOS PAC ID: 1254488422 Enrollment ID: I20191021002885 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ryan M Argyle |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1942614292 PECOS PAC ID: 0042439846 Enrollment ID: I20191028003227 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesse Elyse Chase |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1780097410 PECOS PAC ID: 5193057644 Enrollment ID: I20191101001156 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Esther S Im |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447807532 PECOS PAC ID: 1052643541 Enrollment ID: I20191103000016 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mandeep K Kingra |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750693602 PECOS PAC ID: 0648462473 Enrollment ID: I20191104001159 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dominique Dantes Laron |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1164789079 PECOS PAC ID: 9335432798 Enrollment ID: I20191104001766 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelsey Susan Alama |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598137424 PECOS PAC ID: 5991083693 Enrollment ID: I20191113001081 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yeong Paul Park |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104161777 PECOS PAC ID: 0345495792 Enrollment ID: I20191114002836 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melinda C Burns-williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710351341 PECOS PAC ID: 1456658327 Enrollment ID: I20191115000293 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jade Bergez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174038277 PECOS PAC ID: 4183056963 Enrollment ID: I20191115002270 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Raquel A Bishop |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477102689 PECOS PAC ID: 2567894397 Enrollment ID: I20191118001015 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Burkley Snow |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1336468404 PECOS PAC ID: 7517251465 Enrollment ID: I20191118002230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gaelen Glen Watt |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1124412366 PECOS PAC ID: 9537592936 Enrollment ID: I20191125001605 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brent D Fisk |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1124418561 PECOS PAC ID: 3779916887 Enrollment ID: I20191204000372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer M Brinkman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1053968578 PECOS PAC ID: 3274966270 Enrollment ID: I20191205000998 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Frances K Lawson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1851334387 PECOS PAC ID: 3274520796 Enrollment ID: I20191209001506 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pooja Jasmine Saini |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073971693 PECOS PAC ID: 0244502763 Enrollment ID: I20191210002477 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mardin Sabir |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427537844 PECOS PAC ID: 7012260300 Enrollment ID: I20191223001761 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica A Nicoud |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1295378545 PECOS PAC ID: 9032541081 Enrollment ID: I20191228000364 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kaile Hannah Zaretsky |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831650100 PECOS PAC ID: 7911331798 Enrollment ID: I20200103000206 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julianne Marie Rolfes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669929758 PECOS PAC ID: 2567742703 Enrollment ID: I20200108002017 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sasha E Stanton |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1730348632 PECOS PAC ID: 9133342587 Enrollment ID: I20200110001564 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Logan Havel Buckley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699256990 PECOS PAC ID: 9133479033 Enrollment ID: I20200116002113 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | William K Korbacher |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043664121 PECOS PAC ID: 9537452065 Enrollment ID: I20200122000481 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel Marie Marsh |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1255807145 PECOS PAC ID: 7315372166 Enrollment ID: I20200124000718 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard Jordan Delavan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174161319 PECOS PAC ID: 3072948785 Enrollment ID: I20200127000179 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caroline M Olney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174898795 PECOS PAC ID: 1951525039 Enrollment ID: I20200129001025 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kerani A Tracy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851748370 PECOS PAC ID: 5799066809 Enrollment ID: I20200129001836 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leslie Gildersleeve Bettencourt |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1437799061 PECOS PAC ID: 9638505134 Enrollment ID: I20200131000892 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Neha Balmoori |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962848366 PECOS PAC ID: 7517267842 Enrollment ID: I20200212001117 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brett D Kaylor |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1528407459 PECOS PAC ID: 7113160227 Enrollment ID: I20200311002782 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Moses S Ijaz |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1558325902 PECOS PAC ID: 8820989635 Enrollment ID: I20200317002804 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jean Hannon Mullins-padgett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588207666 PECOS PAC ID: 2062840325 Enrollment ID: I20200319001951 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Peggy E Kelley |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1689777476 PECOS PAC ID: 9335130905 Enrollment ID: I20200324002329 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kendall M Johnson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1073659298 PECOS PAC ID: 9234129107 Enrollment ID: I20200401002721 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lyliane A Chefor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619349966 PECOS PAC ID: 2264738699 Enrollment ID: I20200407001772 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine P Rathbun |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518442391 PECOS PAC ID: 4587900055 Enrollment ID: I20200427002716 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kevin J Koomalsingh |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1528256427 PECOS PAC ID: 5193016145 Enrollment ID: I20200428002416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erica N Dickson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881166627 PECOS PAC ID: 2961833132 Enrollment ID: I20200504002304 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gabrielle A Hendel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861885717 PECOS PAC ID: 4688005580 Enrollment ID: I20200508002230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Conor Mcwade |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1992231765 PECOS PAC ID: 0749519817 Enrollment ID: I20200512003174 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole C Tabbal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992350854 PECOS PAC ID: 0749611499 Enrollment ID: I20200512003620 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Inga Giske |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912471228 PECOS PAC ID: 1153752621 Enrollment ID: I20200518000683 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Josie Banks |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1578185559 PECOS PAC ID: 6608207048 Enrollment ID: I20200519000840 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian S Hough |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1831252782 PECOS PAC ID: 1951371418 Enrollment ID: I20200519002273 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Anne Sorensen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1285943498 PECOS PAC ID: 9436570512 Enrollment ID: I20200527001949 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vidang Nguyen |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1154663987 PECOS PAC ID: 3072830322 Enrollment ID: I20200610002234 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenifer N Lentz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851785513 PECOS PAC ID: 7315290038 Enrollment ID: I20200610003300 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael Layoun |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1992123475 PECOS PAC ID: 7012280712 Enrollment ID: I20200611000805 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gabrielle Simone Alexander |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1124480413 PECOS PAC ID: 4284056698 Enrollment ID: I20200611002501 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tyler Wells |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1790217909 PECOS PAC ID: 5698047546 Enrollment ID: I20200612000330 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas Raines-morris |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205369873 PECOS PAC ID: 8022382605 Enrollment ID: I20200612000713 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey Sun |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457743296 PECOS PAC ID: 5698044709 Enrollment ID: I20200612001326 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kishan Sunilbhai Patel |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1962889634 PECOS PAC ID: 3375878036 Enrollment ID: I20200612002356 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heidi J Hansen |
|---|---|
| Provider Type | Practitioner - Other (physician) |
| Provider Identifiers | NPI Number: 1063655967 PECOS PAC ID: 0244402162 Enrollment ID: I20200612002440 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jason Shawn Nathanael Bensch |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1164765111 PECOS PAC ID: 0648411165 Enrollment ID: I20200615000811 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sayali Kulkarni |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821647140 PECOS PAC ID: 0143642314 Enrollment ID: I20200616001571 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Elizabeth Swift-taylor |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1366837684 PECOS PAC ID: 3476975665 Enrollment ID: I20200616002937 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rahul Lauhan |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1245591189 PECOS PAC ID: 1850713991 Enrollment ID: I20200618002963 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hasnain Hasham |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1336568369 PECOS PAC ID: 5193022093 Enrollment ID: I20200619002310 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jacob J Sheff |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1871860676 PECOS PAC ID: 1456683168 Enrollment ID: I20200629003604 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenna N Otter |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1295116671 PECOS PAC ID: 2668765181 Enrollment ID: I20200701000599 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nadia Reinhart-mcmillan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750813507 PECOS PAC ID: 5597037929 Enrollment ID: I20200707001266 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Robin Caitlin Richards |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1700240165 PECOS PAC ID: 7911320874 Enrollment ID: I20200710000363 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susan Blasi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164877023 PECOS PAC ID: 6406146760 Enrollment ID: I20200716003629 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hannah Wolfer |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1649702903 PECOS PAC ID: 7517231442 Enrollment ID: I20200716003926 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer H Nguyen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629505235 PECOS PAC ID: 6103194931 Enrollment ID: I20200717000087 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yilun Koethe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982022778 PECOS PAC ID: 8123361417 Enrollment ID: I20200720000600 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Natalie Alexandra Galvan |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1760038111 PECOS PAC ID: 8224452230 Enrollment ID: I20200723001936 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dustin Cheney |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1669825550 PECOS PAC ID: 5799040622 Enrollment ID: I20200727003467 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen Werner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1184010027 PECOS PAC ID: 6103126339 Enrollment ID: I20200728001399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Roxanne Thomas |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578099859 PECOS PAC ID: 5496024598 Enrollment ID: I20200728001822 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer S Muong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013301076 PECOS PAC ID: 0749548311 Enrollment ID: I20200728003869 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zachary P Muscato |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1124480264 PECOS PAC ID: 0042504706 Enrollment ID: I20200730000856 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristina Brittany Moon |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1124361241 PECOS PAC ID: 9234367459 Enrollment ID: I20200730001962 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ari R Tallen |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1306286133 PECOS PAC ID: 6002100674 Enrollment ID: I20200731001756 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katie Elizabeth Yonker |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1366785313 PECOS PAC ID: 8729229216 Enrollment ID: I20200805000473 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa Pearson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720412901 PECOS PAC ID: 6800169996 Enrollment ID: I20200805001948 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Esther Wright |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538551445 PECOS PAC ID: 9032482302 Enrollment ID: I20200806003378 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven T Phan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740613314 PECOS PAC ID: 1456629286 Enrollment ID: I20200817003575 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kara R Johansen |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1124220389 PECOS PAC ID: 6608065842 Enrollment ID: I20200819003285 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarthak Sahu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942720883 PECOS PAC ID: 0749606838 Enrollment ID: I20200819004097 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Luke C Clifford |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750825931 PECOS PAC ID: 3476890526 Enrollment ID: I20200825003426 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica L Lea |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1902104078 PECOS PAC ID: 0840617247 Enrollment ID: I20200831002650 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Logan W Guckien |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649708710 PECOS PAC ID: 0143591008 Enrollment ID: I20200831002854 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jean-huei Yau |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346603792 PECOS PAC ID: 0345536611 Enrollment ID: I20200901002743 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vihangi Hindagolla |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346621232 PECOS PAC ID: 8325329436 Enrollment ID: I20200909000311 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jon Michael Gerry |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1225353824 PECOS PAC ID: 5395052252 Enrollment ID: I20200909002048 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward M Kim |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487180667 PECOS PAC ID: 7012286115 Enrollment ID: I20200909002616 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael J Silvas |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1568999183 PECOS PAC ID: 0648548479 Enrollment ID: I20200909003336 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joanne Debrah |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942646518 PECOS PAC ID: 2163651464 Enrollment ID: I20200914001555 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kayla Kealoha Guillory |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1972041515 PECOS PAC ID: 0749608941 Enrollment ID: I20200921002496 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shidrokh Taeidi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780110205 PECOS PAC ID: 5698046662 Enrollment ID: I20200925000953 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca Ann Madore |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1336389246 PECOS PAC ID: 6204255151 Enrollment ID: I20200928000925 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsay S Moore |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1083227805 PECOS PAC ID: 7618396334 Enrollment ID: I20200930001135 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher J Darus |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1912026600 PECOS PAC ID: 6406947050 Enrollment ID: I20200930002563 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Annelise Michelle Manns |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1316562424 PECOS PAC ID: 5395164743 Enrollment ID: I20201005000085 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Catherine Danford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922463587 PECOS PAC ID: 7214236298 Enrollment ID: I20201009002350 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Michael Rodriguez |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1679885479 PECOS PAC ID: 0244650802 Enrollment ID: I20201020002168 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maria Ann Moritz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1871049940 PECOS PAC ID: 7214347350 Enrollment ID: I20201102001117 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eric Timmons |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588262687 PECOS PAC ID: 3779994033 Enrollment ID: I20201118001418 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Abhinav Nafday |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1013397256 PECOS PAC ID: 0547574006 Enrollment ID: I20201203000728 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia Aretha Phillips |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1316091952 PECOS PAC ID: 2860803368 Enrollment ID: I20201203002462 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katy L Bochat |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003200908 PECOS PAC ID: 2062781859 Enrollment ID: I20201204000218 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Irina Gelman |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1437413317 PECOS PAC ID: 5698186138 Enrollment ID: I20201204001156 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kaitlyn M Mcgowan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619513769 PECOS PAC ID: 0143658328 Enrollment ID: I20201204001284 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Henry A Lauer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1346645975 PECOS PAC ID: 7012329378 Enrollment ID: I20201210002746 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily C Stevens |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1588269880 PECOS PAC ID: 0446662704 Enrollment ID: I20201210002916 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leah Burke Chapman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487251773 PECOS PAC ID: 6305258476 Enrollment ID: I20201214002308 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alicia Nicole Carter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558791186 PECOS PAC ID: 8921410895 Enrollment ID: I20201217001077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Francis G Bell |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1982846473 PECOS PAC ID: 2961623624 Enrollment ID: I20201222002941 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristina Lynn Downes |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1821415274 PECOS PAC ID: 2466865084 Enrollment ID: I20201228001890 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsey Ann Wilson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1740886100 PECOS PAC ID: 6507279759 Enrollment ID: I20210106002462 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Travis B Vandinh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326646118 PECOS PAC ID: 8628481439 Enrollment ID: I20210114002139 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Angela M Vitek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841797990 PECOS PAC ID: 9436414919 Enrollment ID: I20210126002477 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Risa Rothmann Siegel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619267887 PECOS PAC ID: 6204052004 Enrollment ID: I20210209001816 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Dunaway |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1396332508 PECOS PAC ID: 1951716463 Enrollment ID: I20210216000815 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ryan E Harris |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1063734796 PECOS PAC ID: 0345655890 Enrollment ID: I20210216002031 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David Matthew Buchan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376184143 PECOS PAC ID: 0749511384 Enrollment ID: I20210222001761 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer M Beckley Hays |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154897874 PECOS PAC ID: 7012323298 Enrollment ID: I20210312001787 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashlea Anne Stanford |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508100561 PECOS PAC ID: 1052728508 Enrollment ID: I20210329001661 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica J Bonilla |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1710593967 PECOS PAC ID: 1456768936 Enrollment ID: I20210330000155 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caitlin Connor Ansel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588251532 PECOS PAC ID: 2961810841 Enrollment ID: I20210413002411 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Adeline Plesiu |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1104168608 PECOS PAC ID: 3678707544 Enrollment ID: I20210503001492 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas David Sanderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275171316 PECOS PAC ID: 3971912726 Enrollment ID: I20210506001364 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cameron Miles Long |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1013344506 PECOS PAC ID: 6305131970 Enrollment ID: I20210513001247 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carolyn R Meisner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1861074965 PECOS PAC ID: 3274942784 Enrollment ID: I20210513002613 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Claire Christina Ford |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1366948622 PECOS PAC ID: 3779834361 Enrollment ID: I20210524000399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher Edward Komisarz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134660640 PECOS PAC ID: 8820321011 Enrollment ID: I20210527001219 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristian E Flores |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1104120195 PECOS PAC ID: 9335417179 Enrollment ID: I20210527001776 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Annika A Ginsberg |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1235406018 PECOS PAC ID: 1850559014 Enrollment ID: I20210527001782 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Clayton Scott Robinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881275006 PECOS PAC ID: 5193124832 Enrollment ID: I20210528001172 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Uma Pisharody |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1063602555 PECOS PAC ID: 9537210034 Enrollment ID: I20210528002278 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Riann Kathleen Thayer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164091898 PECOS PAC ID: 5193126662 Enrollment ID: I20210622003255 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah M Iregui |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770673444 PECOS PAC ID: 1456252535 Enrollment ID: I20210623001215 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua Genstler |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669963716 PECOS PAC ID: 5294081949 Enrollment ID: I20210623001518 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathryn Mcgonigle |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1417042854 PECOS PAC ID: 1850332081 Enrollment ID: I20210624000000 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daina Gakima Ngugi |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1356788376 PECOS PAC ID: 5799927661 Enrollment ID: I20210624003800 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evthokia Hobbs |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1326433475 PECOS PAC ID: 7012224132 Enrollment ID: I20210706002862 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexandra Reinbold |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1831696319 PECOS PAC ID: 0143579276 Enrollment ID: I20210707003203 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher Story |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1679077648 PECOS PAC ID: 6204186885 Enrollment ID: I20210707003261 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brieanna R Brown |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861843351 PECOS PAC ID: 0244586998 Enrollment ID: I20210709002700 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Boris M Rozenberg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861982530 PECOS PAC ID: 7911254495 Enrollment ID: I20210712002782 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andre E Heiber |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730667080 PECOS PAC ID: 1254734460 Enrollment ID: I20210726003356 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachael Marie Carreno |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144753914 PECOS PAC ID: 8921353244 Enrollment ID: I20210727002790 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James Howard Kurtz |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1992046825 PECOS PAC ID: 9537469663 Enrollment ID: I20210727003768 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew W Haley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154813889 PECOS PAC ID: 0244583680 Enrollment ID: I20210728002344 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julia E Fehniger |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1245679984 PECOS PAC ID: 1153623921 Enrollment ID: I20210729001377 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zheng Z Topp |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1023212784 PECOS PAC ID: 9638357122 Enrollment ID: I20210729002483 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sebastian J Reeve |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1588153787 PECOS PAC ID: 5698022853 Enrollment ID: I20210730001488 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Aaron B Summers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215423298 PECOS PAC ID: 7416201348 Enrollment ID: I20210802001204 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sylvia M Peterson-perry |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336522747 PECOS PAC ID: 7315295375 Enrollment ID: I20210802003142 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jin H Cai |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1174973358 PECOS PAC ID: 0446543359 Enrollment ID: I20210802003162 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily M Lin |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1598149650 PECOS PAC ID: 1153725932 Enrollment ID: I20210802003355 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Taylor Krieg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1326400573 PECOS PAC ID: 6800149485 Enrollment ID: I20210803003402 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Raphael C Sun |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1831410349 PECOS PAC ID: 0042524225 Enrollment ID: I20210805001535 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chloe Ann Shmays |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699377267 PECOS PAC ID: 2365846763 Enrollment ID: I20210806002099 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer C Moshman |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194212092 PECOS PAC ID: 7810249927 Enrollment ID: I20210809001843 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Isabella Giroux Pribyl Givens |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1427608470 PECOS PAC ID: 3375947690 Enrollment ID: I20210810000141 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Heidi N Reich |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1326575937 PECOS PAC ID: 9830467661 Enrollment ID: I20210810004167 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elisabeth C Hootman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851822399 PECOS PAC ID: 8527338383 Enrollment ID: I20210811004277 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jonathan Lowy |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1619926300 PECOS PAC ID: 6406957794 Enrollment ID: I20210812000399 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Reny Emmaline Ferrari |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1073093043 PECOS PAC ID: 3375947336 Enrollment ID: I20210812002336 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa Louise Desouza |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1902224694 PECOS PAC ID: 1850519687 Enrollment ID: I20210813002476 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Suartcha Prueksaritanond |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1306129663 PECOS PAC ID: 4284852146 Enrollment ID: I20210813003087 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexander Boscanin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1245618859 PECOS PAC ID: 2466730650 Enrollment ID: I20210816002561 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stuart Malcolm |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1124472055 PECOS PAC ID: 5890025852 Enrollment ID: I20210821000372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jillian M Catral |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730679499 PECOS PAC ID: 9739435496 Enrollment ID: I20210825001388 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ian M Lentz |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1467806893 PECOS PAC ID: 3577800192 Enrollment ID: I20210825004286 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cristina E Zadroga |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1740438365 PECOS PAC ID: 2668614017 Enrollment ID: I20210826001375 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shraddha K Oza |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1689184160 PECOS PAC ID: 7810392925 Enrollment ID: I20210826002542 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thomas J Phillips |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1548624232 PECOS PAC ID: 5496041923 Enrollment ID: I20210827002262 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Walcott Sapp |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1811263080 PECOS PAC ID: 2668617325 Enrollment ID: I20210908002017 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mackenzie E Michalski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235686411 PECOS PAC ID: 7517247737 Enrollment ID: I20210908002943 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patricia R Nguyen |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1144892290 PECOS PAC ID: 8527464098 Enrollment ID: I20210908002984 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Suzanne Funkhouser |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1124451521 PECOS PAC ID: 3476825381 Enrollment ID: I20210908003570 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashlee Beth Mitchell Von Buttlar |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1982105862 PECOS PAC ID: 2264838614 Enrollment ID: I20210909002360 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Colin Dupree Gause |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1801152509 PECOS PAC ID: 2163794306 Enrollment ID: I20210909003568 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Meghan Rose Hansen |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1699449876 PECOS PAC ID: 1850798471 Enrollment ID: I20210924001222 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Catherine Justice |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1376097055 PECOS PAC ID: 3577960996 Enrollment ID: I20210927002747 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jerry G Elliott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114152758 PECOS PAC ID: 8527235530 Enrollment ID: I20210927003295 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anna K Hoenig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740851336 PECOS PAC ID: 8921406166 Enrollment ID: I20211001002025 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jane G Hobart |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1619121670 PECOS PAC ID: 4688072689 Enrollment ID: I20211005003301 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David W Stanley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1215235965 PECOS PAC ID: 2961745278 Enrollment ID: I20211013001965 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Quy Thi Nguyen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871885194 PECOS PAC ID: 5698902567 Enrollment ID: I20211019002618 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory Glenn Kautz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518458926 PECOS PAC ID: 4284022310 Enrollment ID: I20211022000868 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dipal Dilipbhai Patel |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1780981563 PECOS PAC ID: 8022338268 Enrollment ID: I20211102001970 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda Michele Hinojosa |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1285283358 PECOS PAC ID: 8224427661 Enrollment ID: I20211105001077 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ramey I Volk |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790312353 PECOS PAC ID: 8224427539 Enrollment ID: I20211108001131 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Talya L Miller |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1558788976 PECOS PAC ID: 7315362787 Enrollment ID: I20211108001151 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Richard N Cam |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1316438468 PECOS PAC ID: 3577819234 Enrollment ID: I20211108001940 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura S Braunstein |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1326202458 PECOS PAC ID: 4284864984 Enrollment ID: I20211108002105 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie M Barayuga |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1295225951 PECOS PAC ID: 2668728312 Enrollment ID: I20211111000029 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amrou Ali Idris |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1932528213 PECOS PAC ID: 9335448463 Enrollment ID: I20211129002422 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth A Wong |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1689024432 PECOS PAC ID: 9234529520 Enrollment ID: I20211130002134 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vincent R Quintos |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770928228 PECOS PAC ID: 3971740952 Enrollment ID: I20211201001854 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shruti Vakil |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720391493 PECOS PAC ID: 1951531904 Enrollment ID: I20211202002453 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Susannah J Wright |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1528472487 PECOS PAC ID: 0244620334 Enrollment ID: I20211203001474 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katerina Erokhina |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1437404571 PECOS PAC ID: 8729334784 Enrollment ID: I20211213001824 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan Rose Leon Guerrero |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1013434083 PECOS PAC ID: 7810388337 Enrollment ID: I20211216002604 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ura Stokke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457020752 PECOS PAC ID: 7012308307 Enrollment ID: I20211221001638 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Phoebe Hiu-nam Luc |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1487311171 PECOS PAC ID: 1355732603 Enrollment ID: I20211222001014 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Natasha C Edwin |
|---|---|
| Provider Type | Practitioner - Hematology |
| Provider Identifiers | NPI Number: 1063767317 PECOS PAC ID: 1153678800 Enrollment ID: I20220105000852 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John A Yates |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295224392 PECOS PAC ID: 5294082459 Enrollment ID: I20220105002556 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joshua A Morris |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1093327140 PECOS PAC ID: 1254750441 Enrollment ID: I20220106000956 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsay B Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841872967 PECOS PAC ID: 3678964392 Enrollment ID: I20220106001200 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jaaron T Smith |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1093184483 PECOS PAC ID: 4486045119 Enrollment ID: I20220106001732 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lily A Iteld |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1487936753 PECOS PAC ID: 1850782590 Enrollment ID: I20220106002129 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Navjit Dharampal |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1821607201 PECOS PAC ID: 0648698498 Enrollment ID: I20220106002630 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zinnat Begum |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821415720 PECOS PAC ID: 7012135767 Enrollment ID: I20220110000247 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa Skinner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952773764 PECOS PAC ID: 3870985013 Enrollment ID: I20220119002382 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily Christine Morgan |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1669992541 PECOS PAC ID: 1850783655 Enrollment ID: I20220127001260 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marlyn Kato |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1316518095 PECOS PAC ID: 2769874551 Enrollment ID: I20220128001746 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine Canada Trumbo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194155804 PECOS PAC ID: 4688897853 Enrollment ID: I20220128002223 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shelby L Mulrennan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023775178 PECOS PAC ID: 5395138879 Enrollment ID: I20220204000960 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer K Coffey |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1316544687 PECOS PAC ID: 6709279151 Enrollment ID: I20220207001146 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Diane Michelle Brace |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598427296 PECOS PAC ID: 5496148850 Enrollment ID: I20220207001694 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Eli Arusi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629336995 PECOS PAC ID: 3476869124 Enrollment ID: I20220214000714 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jane E Parker |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1588045173 PECOS PAC ID: 0345633343 Enrollment ID: I20220216000849 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeremy Pottash |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1497142046 PECOS PAC ID: 9931443470 Enrollment ID: I20220217001488 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hao Kee Ho |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1649791385 PECOS PAC ID: 3779993522 Enrollment ID: I20220217001604 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Udip Dahal |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1164733911 PECOS PAC ID: 9335389246 Enrollment ID: I20220217002707 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth D Clements |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1063822435 PECOS PAC ID: 3476810524 Enrollment ID: I20220218001760 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joanna M Bove |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467017046 PECOS PAC ID: 7618202003 Enrollment ID: I20220222002325 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica L Semaan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205353364 PECOS PAC ID: 4385903830 Enrollment ID: I20220225000549 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashley N Lanehurst |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1083235105 PECOS PAC ID: 7416375985 Enrollment ID: I20220303002203 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren W Fisher |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1215253778 PECOS PAC ID: 2567688583 Enrollment ID: I20220304000555 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeremiah Wright |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184921157 PECOS PAC ID: 8123316718 Enrollment ID: I20220304000763 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gefei A Zhu |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1518329804 PECOS PAC ID: 1153749700 Enrollment ID: I20220304001176 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Leffler Wagoner |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1700319688 PECOS PAC ID: 9335533546 Enrollment ID: I20220304001347 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristina S Kezar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1669452348 PECOS PAC ID: 9436174828 Enrollment ID: I20220308001069 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nora M Lersch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639253115 PECOS PAC ID: 6204858970 Enrollment ID: I20220310001438 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelcie L Gerry |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295480887 PECOS PAC ID: 5698160588 Enrollment ID: I20220310002230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erik R Vanderlip |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1306044524 PECOS PAC ID: 3173719663 Enrollment ID: I20220321001168 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melanie Janel Boney |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1528609161 PECOS PAC ID: 0840685095 Enrollment ID: I20220324002277 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patrick W Young |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164879649 PECOS PAC ID: 7113218058 Enrollment ID: I20220404002101 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelsey J Peck |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003482787 PECOS PAC ID: 0648678995 Enrollment ID: I20220407001230 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Rae Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346999737 PECOS PAC ID: 9638565229 Enrollment ID: I20220407001297 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tamara L Divino |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386300739 PECOS PAC ID: 8224424742 Enrollment ID: I20220411001303 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew C Fischer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1811382922 PECOS PAC ID: 5698068195 Enrollment ID: I20220411001580 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melissa M Lin |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1659735751 PECOS PAC ID: 5991091225 Enrollment ID: I20220427002246 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Malin Suzan Adams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437824224 PECOS PAC ID: 5597152207 Enrollment ID: I20220427003160 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John Lyle Tron Gomez |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1316389273 PECOS PAC ID: 2567705650 Enrollment ID: I20220428001450 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Teresa A Davigo |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1932421393 PECOS PAC ID: 2264829878 Enrollment ID: I20220429001349 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marley Carla King |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275172066 PECOS PAC ID: 7214324698 Enrollment ID: I20220504000666 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rosmili Villavicencio-dunlap |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659840650 PECOS PAC ID: 1850788167 Enrollment ID: I20220504002430 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth A Beswick |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1356550362 PECOS PAC ID: 5890878011 Enrollment ID: I20220509001483 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan Marie Connolly |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497401491 PECOS PAC ID: 5092192146 Enrollment ID: I20220511002499 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Juan C Iregui |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1336191618 PECOS PAC ID: 1254318009 Enrollment ID: I20220517002204 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Erica Marie Capretta |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427432145 PECOS PAC ID: 9032454095 Enrollment ID: I20220517002432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher M Bender |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003470238 PECOS PAC ID: 4587998109 Enrollment ID: I20220520001755 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chang Min Lee |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962066100 PECOS PAC ID: 0446584924 Enrollment ID: I20220621003051 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jooim Yang |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619619772 PECOS PAC ID: 0446639389 Enrollment ID: I20220622003372 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Marissa Ann Montejano |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1821739368 PECOS PAC ID: 2567841265 Enrollment ID: I20220627003408 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Caleb P Prentice |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700231347 PECOS PAC ID: 2668738642 Enrollment ID: I20220628003005 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alexandra Julienne Wiggins |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376004077 PECOS PAC ID: 6507109493 Enrollment ID: I20220628003472 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jenny Tran Lee |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1841724028 PECOS PAC ID: 4880928688 Enrollment ID: I20220706003101 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samyon Y Itzhakov |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1528622768 PECOS PAC ID: 6204160799 Enrollment ID: I20220708002459 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony Cao Hung Nguyen |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1346696317 PECOS PAC ID: 3274884879 Enrollment ID: I20220719000558 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maggie J Haworth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437896149 PECOS PAC ID: 8123409281 Enrollment ID: I20220720002528 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelsey S Tanaka |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649727348 PECOS PAC ID: 4789972175 Enrollment ID: I20220726000665 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth S Severson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1073048450 PECOS PAC ID: 9537494034 Enrollment ID: I20220726001565 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Drew M Houston |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1285175604 PECOS PAC ID: 0042614174 Enrollment ID: I20220726002762 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Neda Dee Jooya |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1588059638 PECOS PAC ID: 9234472390 Enrollment ID: I20220726003199 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anjali Jaba Das |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891228573 PECOS PAC ID: 3779850201 Enrollment ID: I20220727000778 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amber N Ruiz |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1144754292 PECOS PAC ID: 0648542597 Enrollment ID: I20220728002944 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Natalie C Yin |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1215340450 PECOS PAC ID: 4284987884 Enrollment ID: I20220804000715 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Garrett David Lui |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1962991133 PECOS PAC ID: 8527394253 Enrollment ID: I20220808003138 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew Balster |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1356803159 PECOS PAC ID: 9032448204 Enrollment ID: I20220808003366 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sean Carosso Brachvogel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1184288011 PECOS PAC ID: 6507190097 Enrollment ID: I20220812001048 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Douglas J Ammerman |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740622604 PECOS PAC ID: 1153688825 Enrollment ID: I20220812002876 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa Lynn Perreault |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437637832 PECOS PAC ID: 9830572171 Enrollment ID: I20220818001843 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Raagav Mohanakrishnan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750841193 PECOS PAC ID: 8022347236 Enrollment ID: I20220823002256 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Shu Ya Xie |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1427612332 PECOS PAC ID: 1951635515 Enrollment ID: I20220824001913 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Molly Ann Fauske |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013495704 PECOS PAC ID: 8123402146 Enrollment ID: I20220825000382 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sylvia Shaykis |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1659759421 PECOS PAC ID: 1850775826 Enrollment ID: I20220825002129 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Darius Graeff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780180539 PECOS PAC ID: 6901140177 Enrollment ID: I20220829001635 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hannah Kadavy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922662857 PECOS PAC ID: 3375877996 Enrollment ID: I20220829002190 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie M Day |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1184202145 PECOS PAC ID: 6406245539 Enrollment ID: I20220829002610 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren E Moore |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528509445 PECOS PAC ID: 6103150628 Enrollment ID: I20220829002835 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Logan L Vincent |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1164764288 PECOS PAC ID: 4688991946 Enrollment ID: I20220829003393 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Faith Dieleman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942860994 PECOS PAC ID: 1658778568 Enrollment ID: I20220830003880 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda C Kerber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265670129 PECOS PAC ID: 9032258926 Enrollment ID: I20220831000229 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Candice K Lee |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104117654 PECOS PAC ID: 4082914908 Enrollment ID: I20220902002170 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michael John Paisley |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1700260288 PECOS PAC ID: 6800270208 Enrollment ID: I20220902002381 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hyung Jun Kim |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992970206 PECOS PAC ID: 6103967294 Enrollment ID: I20220902002784 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Michelle Melnik |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811623416 PECOS PAC ID: 3173907581 Enrollment ID: I20220902002903 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Daniel L Junck |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1851300974 PECOS PAC ID: 0648228981 Enrollment ID: I20220903000371 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly Alyse Britsch |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578120630 PECOS PAC ID: 7113325390 Enrollment ID: I20220907001491 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew Szvetecz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1326086950 PECOS PAC ID: 8224941281 Enrollment ID: I20220914001471 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nevin Masri |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487382966 PECOS PAC ID: 6709261373 Enrollment ID: I20220917000360 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gina Christina Meredith |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376796995 PECOS PAC ID: 7517342702 Enrollment ID: I20220925000032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sydney Reynolds Neumann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588392849 PECOS PAC ID: 5991180184 Enrollment ID: I20220926000320 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Timothy Duh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528625878 PECOS PAC ID: 4486988987 Enrollment ID: I20220927001833 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth Margaret Mccaskey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174084925 PECOS PAC ID: 8022346337 Enrollment ID: I20220927002268 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine E Henson |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1215657895 PECOS PAC ID: 6204212327 Enrollment ID: I20220927002594 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shannon Marie Howard |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1144639691 PECOS PAC ID: 1850783275 Enrollment ID: I20220927003201 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tyler J Reimann |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629503966 PECOS PAC ID: 8921333444 Enrollment ID: I20220929002634 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelly M Harrington |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1619409786 PECOS PAC ID: 4082985742 Enrollment ID: I20220929002744 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sheetal K Mehndiratta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619321437 PECOS PAC ID: 9830447242 Enrollment ID: I20220929003167 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy B Waters |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1861997280 PECOS PAC ID: 6901282813 Enrollment ID: I20220929003222 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew Touati |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1730671645 PECOS PAC ID: 5991181802 Enrollment ID: I20220929003289 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Paulina Janelle Fransway |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1841751690 PECOS PAC ID: 7517293939 Enrollment ID: I20220929003329 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Vineet K Mehndiratta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649634940 PECOS PAC ID: 2062760192 Enrollment ID: I20220929003416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | David J Chen |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1679867832 PECOS PAC ID: 9931475605 Enrollment ID: I20220929003932 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew A Joyce |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1194136036 PECOS PAC ID: 8426353343 Enrollment ID: I20221003003176 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Clare Bohnett |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1710482013 PECOS PAC ID: 2769896562 Enrollment ID: I20221006002855 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alisa R Awtry |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801213137 PECOS PAC ID: 4587966148 Enrollment ID: I20221006003413 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lisa M Gonzalez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578291118 PECOS PAC ID: 6204212715 Enrollment ID: I20221007000035 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessamyn Ann Bothwell |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1033845300 PECOS PAC ID: 5193101509 Enrollment ID: I20221007000523 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Katherine E Cobb |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851955785 PECOS PAC ID: 2769716273 Enrollment ID: I20221007000599 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Andrew J Rodriguez |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1245885169 PECOS PAC ID: 5597189027 Enrollment ID: I20221007000914 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chenyong Xiang |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114655636 PECOS PAC ID: 9436535861 Enrollment ID: I20221007001228 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Abby K Murphy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1982195384 PECOS PAC ID: 2264782085 Enrollment ID: I20221010000610 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gillian Seton |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1760635817 PECOS PAC ID: 1658511860 Enrollment ID: I20221011001787 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristen Sarah Thurman |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1841725223 PECOS PAC ID: 5092181305 Enrollment ID: I20221011002236 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ashley D Molina |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1427410703 PECOS PAC ID: 8729402094 Enrollment ID: I20221011002778 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelley Nicole Newton |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508305723 PECOS PAC ID: 9335473891 Enrollment ID: I20221012000505 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | India Lea Leon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841927258 PECOS PAC ID: 5193191443 Enrollment ID: I20221012001080 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole N Ransbottom |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255065330 PECOS PAC ID: 7517333792 Enrollment ID: I20221012002587 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Peter M Dejong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750887493 PECOS PAC ID: 0446507834 Enrollment ID: I20221012002781 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Catharine Aune |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437573086 PECOS PAC ID: 6002039997 Enrollment ID: I20221013000180 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kaylene A Matsuzaki |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1942812060 PECOS PAC ID: 5395111553 Enrollment ID: I20221013001839 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elena D Deweese |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1508531823 PECOS PAC ID: 3971900333 Enrollment ID: I20221017003274 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shanik Joseph Fernando |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1538514179 PECOS PAC ID: 0941580179 Enrollment ID: I20221018001363 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maureen C Andersen |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1851982904 PECOS PAC ID: 8123494978 Enrollment ID: I20221019000498 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel E Gilbert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609384866 PECOS PAC ID: 8426318551 Enrollment ID: I20221019001872 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher John Renner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1023765468 PECOS PAC ID: 0143696898 Enrollment ID: I20221020001195 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Colin M Bosma |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1851060446 PECOS PAC ID: 4183090533 Enrollment ID: I20221026001700 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lucie M Russ |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1992360200 PECOS PAC ID: 1951777333 Enrollment ID: I20221026003144 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Josiah A Cobb |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821579053 PECOS PAC ID: 9638546070 Enrollment ID: I20221027002699 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica J Tang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104553395 PECOS PAC ID: 8628445079 Enrollment ID: I20221027003166 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jesse Taylor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871944538 PECOS PAC ID: 9739462060 Enrollment ID: I20221103001893 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hanna Pedego |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1801535794 PECOS PAC ID: 3779950605 Enrollment ID: I20221107002421 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jessica K Paxton |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1720596398 PECOS PAC ID: 9830566645 Enrollment ID: I20221108002712 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary E Stoddard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811435373 PECOS PAC ID: 3173895364 Enrollment ID: I20221114000443 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sally J Gildehaus |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1407381882 PECOS PAC ID: 5597133991 Enrollment ID: I20221116000221 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James E Rafferty |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1821160466 PECOS PAC ID: 2466548995 Enrollment ID: I20221118001244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Meghan R Mccarthy |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1306371786 PECOS PAC ID: 2860860939 Enrollment ID: I20221121001856 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicole M Crotty |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1972075687 PECOS PAC ID: 9032587126 Enrollment ID: I20221121002885 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Luka Vlahovic |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1306109772 PECOS PAC ID: 5991007197 Enrollment ID: I20221122000628 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer Marie Kurotobi |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578047858 PECOS PAC ID: 9830567957 Enrollment ID: I20221122002108 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie N Entrikin |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1962128140 PECOS PAC ID: 3274901954 Enrollment ID: I20221130002831 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ahmad Fouad Bayomy |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1942575147 PECOS PAC ID: 5991029571 Enrollment ID: I20221202002843 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Yue Wang |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710695929 PECOS PAC ID: 4688043136 Enrollment ID: I20221206001254 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony A Bouldin |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1164503413 PECOS PAC ID: 7214997931 Enrollment ID: I20221206001717 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shanti Akayla |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1437875556 PECOS PAC ID: 3476922949 Enrollment ID: I20221206002225 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Asad Sattar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1578925863 PECOS PAC ID: 2466784582 Enrollment ID: I20221207002273 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mary Ebueku-smith |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1639514805 PECOS PAC ID: 8426329897 Enrollment ID: I20221219002373 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel M Lanasa |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1265875165 PECOS PAC ID: 7416248497 Enrollment ID: I20221222002106 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Izela Michel |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1639890841 PECOS PAC ID: 8022488345 Enrollment ID: I20230103001371 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leanna M King |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1912489006 PECOS PAC ID: 4486024528 Enrollment ID: I20230105001637 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shi-wei S Hwu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457798217 PECOS PAC ID: 0244533271 Enrollment ID: I20230111001533 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony T Soriano |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306099551 PECOS PAC ID: 2567500952 Enrollment ID: I20230125003320 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Claire Anna Marquez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1497233811 PECOS PAC ID: 1557732609 Enrollment ID: I20230127000602 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Augustine Bernard Cantwell Doblado |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619644002 PECOS PAC ID: 7416328448 Enrollment ID: I20230130001070 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hayley A Hirt |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1154935252 PECOS PAC ID: 6709258718 Enrollment ID: I20230220001763 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elise C Yun |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821715657 PECOS PAC ID: 2567835952 Enrollment ID: I20230306002179 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Fusun Soraya Devose |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982011508 PECOS PAC ID: 3779806849 Enrollment ID: I20230308002324 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathaniel R Miller |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336310945 PECOS PAC ID: 3870897176 Enrollment ID: I20230310001087 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gabor C Mezei |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1841520731 PECOS PAC ID: 8325179914 Enrollment ID: I20230310002614 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carolyn Plaunt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366918310 PECOS PAC ID: 1658745773 Enrollment ID: I20230313000983 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Manvi V Smith |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1346694403 PECOS PAC ID: 7517250525 Enrollment ID: I20230313002876 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christine P Corl |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1538385802 PECOS PAC ID: 3274907043 Enrollment ID: I20230316002892 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tracy Herring |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912137860 PECOS PAC ID: 7719025998 Enrollment ID: I20230317001126 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda M Kallunki |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1194250571 PECOS PAC ID: 3870967672 Enrollment ID: I20230317001505 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Douglas R Barber |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1477520005 PECOS PAC ID: 7911066907 Enrollment ID: I20230320001097 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristina S Kezar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669452348 PECOS PAC ID: 9436174828 Enrollment ID: I20230327001260 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Pimsani Wesley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861104226 PECOS PAC ID: 4981079134 Enrollment ID: I20230331001755 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Morgan M Mousley |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275037368 PECOS PAC ID: 9436514759 Enrollment ID: I20230420000852 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dipesh K C Ghimire |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1295106169 PECOS PAC ID: 4880941848 Enrollment ID: I20230420000965 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lauren Park Martin Pitre |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1376238840 PECOS PAC ID: 3870958119 Enrollment ID: I20230420002020 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chelsey N Chen |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1184337065 PECOS PAC ID: 8224493473 Enrollment ID: I20230424000967 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Juliana Ionescu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306551361 PECOS PAC ID: 5799140885 Enrollment ID: I20230425000188 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dipak B K C |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1013146422 PECOS PAC ID: 3577617406 Enrollment ID: I20230425000989 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Antonya Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679061279 PECOS PAC ID: 6002168432 Enrollment ID: I20230502001779 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda L Nambiar |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1821672395 PECOS PAC ID: 3971968488 Enrollment ID: I20230504001901 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Courtney L Peterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336727007 PECOS PAC ID: 3870997315 Enrollment ID: I20230508001316 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Joseph A. Espero |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427744390 PECOS PAC ID: 3375909500 Enrollment ID: I20230515000683 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gregory W Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821572876 PECOS PAC ID: 0648519595 Enrollment ID: I20230523002699 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brian Keith Sparks |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1780940403 PECOS PAC ID: 6305193434 Enrollment ID: I20230524003043 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Randall L Fink |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417351842 PECOS PAC ID: 9436467917 Enrollment ID: I20230526001805 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Olesea Bonanno |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386128056 PECOS PAC ID: 5496096083 Enrollment ID: I20230531000597 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Catherine Micaela Elzie |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1902186836 PECOS PAC ID: 8123485588 Enrollment ID: I20230531001646 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen A Avera |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174986293 PECOS PAC ID: 4789913971 Enrollment ID: I20230607000249 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kandice D Schultz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861687170 PECOS PAC ID: 1951585991 Enrollment ID: I20230607000971 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Candice M Dolbier |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1629333893 PECOS PAC ID: 8325271661 Enrollment ID: I20230614004018 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sandra Louise Drager |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1205802097 PECOS PAC ID: 9436325354 Enrollment ID: I20230616001707 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bethany L Adams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053955047 PECOS PAC ID: 0840629341 Enrollment ID: I20230616002922 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cody John Paiva |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1821613837 PECOS PAC ID: 1052733698 Enrollment ID: I20230619000412 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Emily Grace Douglass |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982304630 PECOS PAC ID: 6103284138 Enrollment ID: I20230622002403 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura Elizabeth Bennetts |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760006118 PECOS PAC ID: 3870915614 Enrollment ID: I20230626003019 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lucas Mcduffie |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1710269261 PECOS PAC ID: 6709024920 Enrollment ID: I20230706001558 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charlie Dean Foster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083890586 PECOS PAC ID: 4688740368 Enrollment ID: I20230708000285 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Laura Phyllis Perry |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912296799 PECOS PAC ID: 0446534101 Enrollment ID: I20230710003170 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nathaniel Edwards |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1477174076 PECOS PAC ID: 7012339765 Enrollment ID: I20230714002269 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas Gates |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770104713 PECOS PAC ID: 4486076510 Enrollment ID: I20230804001364 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samarth Shivakumar Mathapathi |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1639668767 PECOS PAC ID: 6103246533 Enrollment ID: I20230804002011 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Edward J Kauffman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316323777 PECOS PAC ID: 5395034615 Enrollment ID: I20230808002045 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Evan Hunter Alldredge |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1194276931 PECOS PAC ID: 8224375415 Enrollment ID: I20230809001246 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elizabeth Anne Ribbeck |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1639203540 PECOS PAC ID: 7810089364 Enrollment ID: I20230811003183 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Steven Sha |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1588127427 PECOS PAC ID: 2466886130 Enrollment ID: I20230811003201 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James Lewis Miller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003443391 PECOS PAC ID: 8729440441 Enrollment ID: I20230811003376 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | John D Oholleran |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1912007220 PECOS PAC ID: 9133285224 Enrollment ID: I20230811003404 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kyungjeen Paik |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881196525 PECOS PAC ID: 4385067685 Enrollment ID: I20230814001487 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amy Rochelle Smith |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1609020056 PECOS PAC ID: 6305208976 Enrollment ID: I20230814002457 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Leah M Taylor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124718184 PECOS PAC ID: 0143682724 Enrollment ID: I20230814002780 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan Elizabeth Block |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1265056618 PECOS PAC ID: 2961824701 Enrollment ID: I20230814002931 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Terra Elise D'antonio Dudley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467144568 PECOS PAC ID: 1052773645 Enrollment ID: I20230814003325 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Brooke Janelle Autrey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710504162 PECOS PAC ID: 4082076518 Enrollment ID: I20230816001615 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anthony M Paluso |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669097671 PECOS PAC ID: 0840613246 Enrollment ID: I20230816001699 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberlie Anne Dame |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366134843 PECOS PAC ID: 9931562873 Enrollment ID: I20230825000809 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Maryam M Saudagaran |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083248504 PECOS PAC ID: 8729466776 Enrollment ID: I20230825001975 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Chinmay Paranjape |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1932633799 PECOS PAC ID: 9830476407 Enrollment ID: I20230830001264 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Raj Nagappan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992334999 PECOS PAC ID: 3274957816 Enrollment ID: I20230831004440 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jan Hua |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922635150 PECOS PAC ID: 5698198851 Enrollment ID: I20230901001693 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Thatcher Houldin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578184511 PECOS PAC ID: 7416379540 Enrollment ID: I20230901002321 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Carolyn Jean Mistele |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952072050 PECOS PAC ID: 9335502608 Enrollment ID: I20230905001094 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jakob L Feeney |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720609324 PECOS PAC ID: 7416379557 Enrollment ID: I20230905003550 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shayna Richards |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740933597 PECOS PAC ID: 2466816681 Enrollment ID: I20230906003376 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Nicholas Rigley Williams |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1699255869 PECOS PAC ID: 3274863238 Enrollment ID: I20230907001696 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kylene M Olin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275317802 PECOS PAC ID: 0941664692 Enrollment ID: I20230913002303 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melinda G Honeycutt |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1578929352 PECOS PAC ID: 5597129270 Enrollment ID: I20230913003654 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Samuel B Luty |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1811496409 PECOS PAC ID: 8628490406 Enrollment ID: I20230913004205 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Megan R Chalupsky |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1215436159 PECOS PAC ID: 3779987888 Enrollment ID: I20230915002275 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Bao Tran Ngoc Nhan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326668385 PECOS PAC ID: 1759703770 Enrollment ID: I20230918001037 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alison D Treister |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1518350172 PECOS PAC ID: 7012332737 Enrollment ID: I20230918001311 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mich Andrew Gehrig |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780211680 PECOS PAC ID: 2860818242 Enrollment ID: I20230918002123 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Zoe C Moss |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1205377181 PECOS PAC ID: 8224363460 Enrollment ID: I20230918002244 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rubama Nasir |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629698675 PECOS PAC ID: 4082036892 Enrollment ID: I20230918002579 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca Lee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669198446 PECOS PAC ID: 0749644185 Enrollment ID: I20230918003416 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin R Yu |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1568993590 PECOS PAC ID: 0446521785 Enrollment ID: I20230919002343 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rachel Alina Boneski |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598261372 PECOS PAC ID: 2163844192 Enrollment ID: I20230926001620 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Miranda V Keepers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285010181 PECOS PAC ID: 6204280167 Enrollment ID: I20230926002316 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathryne E Doria |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790374536 PECOS PAC ID: 4587070420 Enrollment ID: I20230928002915 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca Ann Anthony |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1467945006 PECOS PAC ID: 7012262835 Enrollment ID: I20231008000026 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Holly H Omar |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1104912120 PECOS PAC ID: 4082649934 Enrollment ID: I20231016000855 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Taylor Charlotte Wolfgang |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1639660558 PECOS PAC ID: 5597012690 Enrollment ID: I20231101001127 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ilana Pena-sanders |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1083336887 PECOS PAC ID: 2264889757 Enrollment ID: I20231105000032 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jillian Baumberger |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1932523701 PECOS PAC ID: 7618324104 Enrollment ID: I20231105000061 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Michaela Dawn Bowles |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841077211 PECOS PAC ID: 8729435045 Enrollment ID: I20231108002036 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Casseopia Fisher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841078326 PECOS PAC ID: 3870940117 Enrollment ID: I20231108002767 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jeffrey M Stolsig |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679193635 PECOS PAC ID: 4284056144 Enrollment ID: I20231110000838 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Iris R Malit |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1578996518 PECOS PAC ID: 5597051557 Enrollment ID: I20231110001714 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Matthew H Brookes |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1114366424 PECOS PAC ID: 2567711351 Enrollment ID: I20231115002666 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Rebecca M Maher |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609390764 PECOS PAC ID: 1658728357 Enrollment ID: I20231116001961 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Lindsay Kate Kuo |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1003305970 PECOS PAC ID: 0648627372 Enrollment ID: I20231116003052 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Elisabeth Ann Owen |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1154895530 PECOS PAC ID: 5799132478 Enrollment ID: I20231117001218 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dominique Francesca Mann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942998612 PECOS PAC ID: 2365899051 Enrollment ID: I20231117001868 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Christopher Blaine Mikulic |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1548759418 PECOS PAC ID: 4880042910 Enrollment ID: I20231129002115 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Dylan Cordero Young |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821763053 PECOS PAC ID: 8729436647 Enrollment ID: I20231201002262 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melody Rose Lough |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710766795 PECOS PAC ID: 1557710753 Enrollment ID: I20231213002798 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie V Winn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194269910 PECOS PAC ID: 1658720636 Enrollment ID: I20231215002553 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Sarah Fihn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215566922 PECOS PAC ID: 1759709223 Enrollment ID: I20231220002220 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | James T Brown |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700373305 PECOS PAC ID: 8527319656 Enrollment ID: I20231220002283 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly A. Ceccarelli |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609655521 PECOS PAC ID: 6800246471 Enrollment ID: I20231221003142 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Mandie L Webb |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1568879625 PECOS PAC ID: 7012367220 Enrollment ID: I20240102000243 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Amanda C Bossert |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1447608393 PECOS PAC ID: 7012367121 Enrollment ID: I20240102000599 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Diana L Gantt |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1871959833 PECOS PAC ID: 0749630762 Enrollment ID: I20240103000601 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Arissara Miyoshi |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1053633651 PECOS PAC ID: 4981054939 Enrollment ID: I20240103001631 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Garnett Lynn Dittfurth Wong |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1811023310 PECOS PAC ID: 5597115543 Enrollment ID: I20240103001889 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Julie Lorene Mannon |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1639495989 PECOS PAC ID: 6406207448 Enrollment ID: I20240104000360 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Benjamin D Cook |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1881124899 PECOS PAC ID: 8224489299 Enrollment ID: I20240104001125 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Charlene Michelle Negus Shemley |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1669705018 PECOS PAC ID: 1557712536 Enrollment ID: I20240104001669 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shelbe V Hill |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1134313034 PECOS PAC ID: 4587015094 Enrollment ID: I20240109003919 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tia S Nadler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134737521 PECOS PAC ID: 8022469378 Enrollment ID: I20240110005109 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Justine Blaud |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1770012403 PECOS PAC ID: 0749659498 Enrollment ID: I20240111004610 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Alyssa Nicole Crea |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1972881258 PECOS PAC ID: 9436500543 Enrollment ID: I20240112001093 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer Marie Bezanson |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1568950046 PECOS PAC ID: 1355792490 Enrollment ID: I20240112002128 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Shawn M Croskey |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1265559728 PECOS PAC ID: 8426400540 Enrollment ID: I20240113000800 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Madelyn E Trapp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568157535 PECOS PAC ID: 7315399482 Enrollment ID: I20240115001125 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kalindi Hendrix |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1134542004 PECOS PAC ID: 9537511605 Enrollment ID: I20240115001324 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Taylor M Miles |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1043665987 PECOS PAC ID: 5890032353 Enrollment ID: I20240115001468 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Patricia A Beck |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1508021130 PECOS PAC ID: 0941652028 Enrollment ID: I20240115001494 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kelly A Shields |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1083075790 PECOS PAC ID: 1759733736 Enrollment ID: I20240115001783 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Hugo Akabane |
|---|---|
| Provider Type | Practitioner - Hematology |
| Provider Identifiers | NPI Number: 1982010583 PECOS PAC ID: 0941624050 Enrollment ID: I20240116003002 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kimberly Wirth |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1730831140 PECOS PAC ID: 7911359831 Enrollment ID: I20240116004432 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | A Harriet Beeman |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1427027259 PECOS PAC ID: 1153773015 Enrollment ID: I20240117001007 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephanie Thompson-mccollough |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1649675190 PECOS PAC ID: 6709238033 Enrollment ID: I20240122004561 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Cherylynn A Moser |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1205390739 PECOS PAC ID: 2163874413 Enrollment ID: I20240123000595 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Jennifer L Turner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598182289 PECOS PAC ID: 1850515339 Enrollment ID: I20240124000093 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Gina Guillaume |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649705682 PECOS PAC ID: 2961831060 Enrollment ID: I20240124001618 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kyle J Grelle |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1639500549 PECOS PAC ID: 2466805643 Enrollment ID: I20240124003943 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kathryn L Dawson |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1477997724 PECOS PAC ID: 7517192420 Enrollment ID: I20240125002326 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stephen Zeimantz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922001478 PECOS PAC ID: 7719075399 Enrollment ID: I20240201003747 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Ketki Patankar |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1467958777 PECOS PAC ID: 4385087568 Enrollment ID: I20240205001630 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Kristin M Skoch-ogard |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1558662593 PECOS PAC ID: 8921441809 Enrollment ID: I20240207002942 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Anagha Phadkule |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1457903403 PECOS PAC ID: 5294179651 Enrollment ID: I20240214001161 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Melanie D Roedel |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1023339488 PECOS PAC ID: 3072957901 Enrollment ID: I20240220001144 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Stuart D Chin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710754734 PECOS PAC ID: 2264876937 Enrollment ID: I20240221001996 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Danielle L Miller |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790131472 PECOS PAC ID: 4789979907 Enrollment ID: I20240222004343 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
| Provider Name | Tehniyah N Gomez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720724388 PECOS PAC ID: 3678918190 Enrollment ID: I20240223003017 |
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
News Archive
As a result of the recent Salmonella outbreak linked to peanut butter, an extensive inspection of ConAgra's processing plant in Georgia by the U.S. Food and Drug Administration (FDA) has revealed the presence of Salmonella.
USA Today reports that the National Association of State Medicaid Directors may release more information this week about how the federal exchange may be mislabelling people as Medicaid-qualified.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...
Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
› Verified 3 days ago
Kristina E Harp M.d P.c Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 17704 Jean Way, Suite 105, Lake Oswego, OR 97035 Phone: 503-675-6776 Fax: 503-675-2572 | |
Kimberly J. Schleef D.o., Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3701 Carman Dr, Lake Oswego, OR 97035 Phone: 503-635-6555 Fax: 503-635-6557 | |
Dr Pepel Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15880 Quarry Rd, Lake Oswego, OR 97035 Phone: 503-232-3302 Fax: 503-200-2895 | |
Deni R Buss Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14511 Westlake Dr, Suite 100, Lake Oswego, OR 97035 Phone: 503-449-6939 Fax: 503-598-3980 | |
Lake Oswego Family Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4035 Mercantile Dr, Suite 104, Lake Oswego, OR 97035 Phone: 503-635-1350 Fax: 503-635-8470 | |
Kleiman Healthcare Services Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 415 N State St Ste 136, Lake Oswego, OR 97034 Phone: 310-951-3450 |